<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Future Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Future Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">3069</journal-id><journal-id journal-id-type="pmc-domain">futoncol</journal-id><journal-id journal-id-type="publisher-id">FON</journal-id><journal-title-group><journal-title>Future Oncology</journal-title></journal-title-group><issn pub-type="ppub">1479-6694</issn><issn pub-type="epub">1744-8301</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7426751</article-id><article-id pub-id-type="pmcid-ver">PMC7426751.1</article-id><article-id pub-id-type="pmcaid">7426751</article-id><article-id pub-id-type="pmcaiid">7426751</article-id><article-id pub-id-type="pmid">32564612</article-id><article-id pub-id-type="doi">10.2217/fon-2020-0224</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8647-3911</contrib-id><name name-style="western"><surname>Kaumaya</surname><given-names initials="PTP">Pravin TP</given-names></name><xref ref-type="corresp" rid="COR1">*</xref><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><aff id="AFF1"><label>1</label>Department of Obstetrics &amp; Gynecology, College of Medicine, Wexner Medical Center, The James Cancer Hospital &amp; Solove Research Institute, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label>Author for correspondence: Tel.: <phone>+1 614 292 7028</phone>; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Pravin.Kaumaya@osumc.edu">Pravin.Kaumaya@osumc.edu</email></corresp></author-notes><pub-date publication-format="electronic" date-type="pub"><day>21</day><month>6</month><year>2020</year></pub-date><pub-date publication-format="print" date-type="pub"><month>8</month><year>2020</year></pub-date><volume>16</volume><issue>23</issue><issue-id pub-id-type="pmc-issue-id">363338</issue-id><fpage>1767</fpage><lpage>1791</lpage><history><date date-type="received"><day>16</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2020</year></date><date date-type="online"><day>21</day><month>6</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>06</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>19</day><month>08</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-11 05:25:21.133"><day>11</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 Pravin TP Kaumaya</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Attribution-NonCommercial-NoDerivatives 4.0 Unported License</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fon-16-1767.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:title="pdf" xlink:href="fon-16-1767.pdf"/><abstract><p>In light of the numerous US FDA-approved humanized monoclonal antibodies (mAbs) for cancer immunotherapy, it is surprising that the advancement of B-cell epitope vaccines designed to elicit a natural humoral polyclonal antibody response has not gained traction in the immune-oncology landscape. Passive immunotherapy with humanized mAbs (Trastuzumab [Herceptin<sup>&#174;</sup>]; Pertuzumab [Perjeta<sup>&#174;</sup>]) has provided clinical benefit to breast cancer patients, albeit with significant shortcomings including toxicity problems and resistance, high costs, sophisticated therapeutic regimen and long half-life. The role of B-cell humoral immunity in cancer is under appreciated and underdeveloped. We have advanced the idea of active immunotherapy with chimeric B-cell epitope peptides incorporating a &#8216;promiscuous&#8217; T-cell epitope that elicits a polyclonal antibody response, which provides safe, cost&#8211;effective therapeutic advantage over mAbs. We have created a portfolio of validated B-cell peptide epitopes against multiple receptor tyrosine kinases (HER-1, HER-3, IGF-1R and VEGF). We have successfully translated two HER-2 combination B-cell peptide vaccines in Phase I and II clinical trials. We have recently developed an effective novel PD-1 vaccine. In this article, I will review our approaches and strategies that focus on B-cell epitope cancer vaccines.</p></abstract><abstract abstract-type="graphical"><title>Graphical abstract</title><p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fon-16-1767-GA.jpg"/></p></abstract><kwd-group kwd-group-type="author"><title>Keywords:&#8194;</title><kwd>B-cell epitopes</kwd><kwd>combination immunotherapy</kwd><kwd>CT-26/HER-2</kwd><kwd>immuno-oncology</kwd><kwd>PD-1</kwd><kwd>peptide cancer vaccines</kwd><kwd>syngeneic model</kwd></kwd-group><counts><page-count count="25"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>B-cell epitope peptide cancer immunotherapies. Cancer is a major cause of death in developed countries and world-wide, whereas in the USA cancer death is a close second to cardiovascular disease. The financial burden of this disease, and more importantly, the suffering it causes, is immense. There is an obvious and urgent need to speed the development and application of new, more efficacious anticancer therapies. The field of oncology is considerable and encompasses a number of indications. The current clinical landscape of immune-oncology (IO) since 2006, 3362 trials have been launched to test PD-1/PD-L1 monoclonal antibodies (mAbs) alone or in combination with other agents, and 2975 of them are still active as of September 2019 [<xref rid="B1" ref-type="bibr">1</xref>]. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need.</p><p>B-cell epitope vaccines have lagged behind in immunotherapeutic cancer strategies compared with T-cell vaccine attempts both in preclinical and clinical studies. There are only a few groups that have dedicated their research goals to advance B-cell epitope cancer vaccines. There are few if any reviews concerning B-cell epitope cancer vaccines except for our own reviews on the subject likely due to the paucity of research in this area as a majority of studies are focused on T-cell vaccines. I have summarized in a number of review articles our B-cell epitope cancer vaccine strategies on humoral immunity for the past two decades [<xref rid="B2" ref-type="bibr">2&#8211;5</xref>]. A more detailed review in Comprehensive Medicinal Chemistry III, Volume 6 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/B978-0-12-409547-2.12422-9">http://dx.doi.org/10.1016/B978-0-12-409547-2.12422-9</ext-link>) summarizes our work entitled &#8216;<italic toggle="yes">Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R</italic>.&#8217; The precise role of B cells in humoral immunity and in the tumor microenvironment is beginning to be appreciated as it relates to a better understanding of their functions, and to the design of new immunotherapeutic strategies [<xref rid="B6" ref-type="bibr">6</xref>]. An excellent article on B-cell epitope-based vaccination therapy by Kametani <italic toggle="yes">et al.</italic>, reviews the various strategies in this area of research and concludes that peptide vaccines that induce B-cell epitope-specific polyclonal antibodies may be useful against cancers that express high levels of antigens and that respond to passive antibody treatment [<xref rid="B7" ref-type="bibr">7</xref>]. A broad review on peptide-based vaccines in various diseases is summarized by Malonis and colleagues [<xref rid="B8" ref-type="bibr">8</xref>]. An excellent review on peptide materials for cancer immunotherapy discusses the various strategies being applied to the cancer landscape by Zhang and colleagues [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>This article is not intended to cover a comprehensive assessment of the field of cancer vaccines or T-cell peptide vaccines in breast cancer and immunotherapy as there are numerous authoritative reviews that cover these topics in depth focusing entirely on T-cell vaccines, and immunotherapies with check point inhibitors. In this article, I hope to focus the readers and researchers in that there is an immediate opportunity to develop B-cell peptide-based epitope cancer vaccines reminiscent of vaccines for infectious diseases establishing a new urgent paradigm change for humoral immunity.</p><p>This article will summarize B-cell epitope-based vaccines for cancers that overexpress HER-2 in particular breast, colorectal and gastric cancers focusing exclusively on strategies to develop B-cell epitope vaccines for receptor tyrosine kinases (RTKs). I will discuss our more recent contribution in developing B-cell vaccines in IO with emphasis on checkpoint inhibitors (PD-1) and their combination with HER-2-based B-cell vaccines. In this article, I will briefly overview our HER-2 vaccine approaches from bench to the clinic and strategies to overcome resistance mechanism with development of other B-cell vaccines that could be used in combination. Finally, I will elucidate new IO strategies developing PD-1 B-cell epitope vaccines in combination with other vaccines (e.g., HER-2 vaccine).</p><sec disp-level="2" id="S0001"><title>Therapeutic cancer vaccines</title><p>Cancer vaccines targeting various antigens/oncogenes have been subject to a variety of strategies that include dendritic cell (DC) cell-based vaccines, peptide/protein vaccines, whole-cell, dendritic cell, and adoptive therapy, DNA and RNA vaccines and tumor cell vaccines. An excellent review by Hollingsworth and Jansen [<xref rid="B10" ref-type="bibr">10</xref>] summarizes the recent advances in the field of therapeutic vaccines. Therapeutic cancer vaccines have not provided clinical benefit except the ones targeting virus-associated cancers. Thus far, only a tiny handful of trials have shown significant impact for vaccines in patients with advanced cancer. Approval of the first therapeutic vaccine sipuleucel-T (Provenge by the FDA) for the treatment of prostate cancer [<xref rid="B11" ref-type="bibr">11</xref>] was obtained in 2010. The past failures of cancer vaccines are largely due, in part, to the fact that these trials have been conducted in severely compromised cancer patients who have received innumerable immune-suppressing chemotherapeutic regimens. Notwithstanding the complexity of the immune system, the intricate interplay within the tumor microenvironment, and an understanding of the depth of immune suppression and evasion which are just beginning to be appreciated may contribute to the successful design of future cancer vaccines. Additionally, cancer vaccines that have been tested in preclinical studies targeting tumor-associated antigens (TAAs), which are unmutated self-proteins overexpressed in tumor cells, thus necessitating breaking immune tolerance to elicit T-cell responses. The main hurdle that had to be overcome in developing peptide vaccines to TAAs is to &#8216;break tolerance&#8217; through various methods such as strong adjuvants or repeated immunization. These strategies are further detailed in specialized reviews [<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>]. Recently, mutation-derived antigens (neoantigens) have been identified and utilized as targets for cancer vaccines. The realization these neoantigens may be more immunogenic that the previously identified CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) of TAAs has invigorated the T-cell vaccine landscape.</p><sec id="S0002"><title>Peptide T-cell-based cancer vaccines have not delivered on the promise</title><p>The development of peptide cancer vaccines has focused largely on strategies that induce cellular antitumor immune responses targeting CD8<sup>+</sup> CTLs. Peptide-based cancer vaccines (comprehensively reviewed by Hirayama and Nishimura [<xref rid="B14" ref-type="bibr">14</xref>]) focused exclusively on CTLs epitopes identified by numerous predictive algorithms. Although these short peptides (9&#8211;10 amino acid) were able to elicit antitumor responses <italic toggle="yes">in vivo</italic>, their clinical benefit was largely ineffective in many Phase I and II clinical trials. More recently, the design of CD4<sup>+</sup> T-helper cell vaccines has also been advanced to induce effective CD8<sup>+</sup> antitumor responses. Long peptide vaccines (30 multimer) to include both helper and cytotoxic epitopes have also been proposed to be more effective immunogens than the CD8<sup>+</sup> T-cell epitopes of 8&#8211;10 amino acid in length. The inclusion of CD4<sup>+</sup> T-helper cell epitopes in the vaccine with longer peptides can provide some clinical benefit in a small number of cancer patients. There is an ongoing debate whether short peptides representing exact CD4<sup>+</sup> or CD8<sup>+</sup> T-cell epitopes should be used, or rather long peptides which need to be processed intracellularly before presentation on MHC molecules. Many of these peptide vaccines are undergoing clinical trials. T-cell cancer vaccines have been shown to have limited clinical impact despite being capable of generating human CD8<sup>+</sup> T-cell responses to defined cancer antigens. The lack of effective T-cell-based peptide vaccines is likely due to the fact that these tumor-specific T cells were unable to cause regression and rejection of established cancers. A plethora of predictive algorithms to predict CTL epitopes (NetCTL.1.2; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/NetCTL/">www.cbs.dtu.dk/services/NetCTL/</ext-link>) is an online server and a raft of software tools for predicting MHC (class I and II binders) are available to explore binding motifs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cancerimmunity.org/resources/webtools/">http://cancerimmunity.org/resources/webtools/</ext-link>). The recent advancements in the technological and bioinformatics fields enable computer-based approaches for rational design of peptide vaccines [<xref rid="B15" ref-type="bibr">15</xref>]. These predictive algorithms provide tools for identifying the best vaccine candidates. However, none of these algorithms has produced an effective T-cell-based peptide vaccine. The likelihood that single epitopes would be effective in a cancer vaccine is unlikely to be realized in the short term. A greater understanding of tumor immune suppression and failure of T-cell vaccination was provided by Allison and colleagues [<xref rid="B16" ref-type="bibr">16</xref>], who showed that blocking inhibitory checkpoint receptors on T cells could release limits on the activation and maintenance of T-cell effector function. Thus, the future development of successful cellular T-cell vaccines will likely depend on reversing tumor-induced T-cell dysfunction/exhaustion with agents targeting immune checkpoint blockade [<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>].</p></sec><sec id="S0003"><title>Current approved therapies are not ideal &amp; have certain limitations: a case for alternatives</title><p>Over the past two decades, there has been a multitude of agents developed targeting oncogenic RTKs [<xref rid="B19" ref-type="bibr">19&#8211;21</xref>] and many of the FDA-approved therapies have been shown to exhibit significant toxicities [<xref rid="B22" ref-type="bibr">22&#8211;25</xref>]. There have been major advances in the treatment of HER-2-positive breast cancer since the introduction of FDA-approved anti-HER-2 mAbs: trastuzumab (Herceptin<sup>&#174;</sup> [<xref rid="B25" ref-type="bibr">25</xref>]), followed by pertuzumab (Perjeta<sup>&#174;</sup> [<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>]). Combined trastuzumab and pertuzumab has been shown to be a more effective therapeutic strategy in preclinical studies [<xref rid="B28" ref-type="bibr">28</xref>] as well as in Phase III clinical trials. Trastuzumab-DM1 (T-DM1) is a novel chemistry-driven conjugated HER-2 mAb in which the trastuzumab is conjugated with a fungal toxin DM1 (maytansine) is FDA approved [<xref rid="B29" ref-type="bibr">29</xref>]. Fam-trastuzumab deruxtecan-nxki (Enhurtu; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="DS820100">DS820100</ext-link> is a recent antibody-drug conjugate comprising three components: a humanized anti-HER-2 IgG1 mAb with the same amino acid sequence as trastuzumab; a topoisomerase I inhibitor payload, an exatecan derivative; and a tetrapeptide-based cleavable linker has been granted an accelerated approval by the FDA (23 December 2019) for treatment of adult patient with unresectable or metastatic HER-2-positive breast cancer who have received at least two prior lines of anti-HER-2-based regimens in the metastatic setting [<xref rid="B30" ref-type="bibr">30</xref>].</p><p>Many of the FDA-approved humanized mAbs have improved patient survival significantly. The success of Herceptin has engendered the development of other therapeutic antibodies such as rituximab (humanize anti-CD20); cetuximab (chimeric anti-HER-1 antibody) and bevacizumab (humanized anti-VEGF) antibody. Many of these mAbs exert the effects through several mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). More recently, the approval of several checkpoint mAbs such as nivolumab, pembrolizumab and atelozumab has created excitement in the field of IO.</p><p>Despite improvements and advances in current drugs treating metastatic breast cancer (MBC) many patients demonstrate disease progression and show problems of selectivity and efficacy, development of resistance and tolerability issues and unacceptable safety profiles that continue to hamper their clinical acceptance and remain a major therapeutic challenge. Novel combinations with improved clinical activity are therefore needed in patients with metastatic HER-2-positive breast cancer and represent an unmet clinical need. Thus, there has been an increasing demand for safer and newer immunotherapeutic approaches that exploits both the high specificity of vaccines targeting the adaptive immune response and the immunological memory.</p></sec><sec id="S0004"><title>Strengths of B-cell epitope peptide-based cancer vaccine</title><p>The advantages of peptide approaches are summarized in <xref rid="T1" ref-type="table">Table 1</xref>. In general, synthetic peptides are safe, easily synthesized and characterized, and are cost-effective and lack of toxicity. There are several advantages of peptide vaccines (B- or T-epitope-based vaccines) and therapeutics over other cancer vaccine approaches. Active immunotherapy offers many advantages, including tumor specificity and the activation of immune responses against antigens that are selectively expressed by tumor cells. Additional advantages of chimeric B- and T-cell vaccines are exquisite specificity and the potential for a durable treatment effect that can be recalled due to immunologic memory [<xref rid="B2" ref-type="bibr">2</xref>]. Therapeutic peptides have been advanced as anticancer agents from basic research to clinical studies and eventually to the pharmaceutical market as they exhibit high selectivity and affinity [<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>]. Peptide mimics, however, modulation of the immune system with peptide mimics as inhibitors could offer several advantages that might be complementary and potentially synergistic to mAb. To overcome the stability problem of the L-peptide inhibitors, retro-inverso D-amino acid peptides can be designed successfully to resist enzymatic degradation and represent potential therapeutic agents with long half-lives <italic toggle="yes">in vivo</italic> and even oral bioavailability [<xref rid="B33" ref-type="bibr">33&#8211;38</xref>]. The advantages and limitations of T-cell epitope vaccines have been extensive reviewed and addressed [<xref rid="B39" ref-type="bibr">39</xref>].</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.<x xml:space="preserve">&#160;</x></label><caption><title>Advantages of B-&amp; T-Cell Epitopes and Peptide Therapeutics.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">As peptide vaccines</th><th align="left" colspan="1" rowspan="1">As peptide therapeutics/T-cell vaccines</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Safe, nontoxic, highly stable, cost effective</td><td align="left" colspan="1" rowspan="1">Safe and viable therapeutic goal</td></tr><tr><td align="left" colspan="1" rowspan="1">Easily manufactured/synthesized/characterized</td><td align="left" colspan="1" rowspan="1">Effective blocking signaling pathways</td></tr><tr><td align="left" colspan="1" rowspan="1">Epitopes are easily identified and predicted</td><td align="left" colspan="1" rowspan="1">High affinity, selectivity and potency</td></tr><tr><td align="left" colspan="1" rowspan="1">Break tumor tolerance</td><td align="left" colspan="1" rowspan="1">Retro-inverso D-amino acid peptides are stable</td></tr><tr><td align="left" colspan="1" rowspan="1">No oncogenic material included and minimal toxicity</td><td align="left" colspan="1" rowspan="1">Reduces off-target side effects</td></tr><tr><td align="left" colspan="1" rowspan="1">Administered by simple routes s.c, im injections</td><td align="left" colspan="1" rowspan="1">Large number of peptide-based drugs being marketed</td></tr><tr><td align="left" colspan="1" rowspan="1">Multi-epitope approach leads to broad antigen recognition and universal coverage</td><td align="left" colspan="1" rowspan="1">No accumulation in specific organs such as kidney and liver minimizing side-effects</td></tr><tr><td align="left" colspan="1" rowspan="1">High affinity, high specificity, strong potency and improved safety profiles</td><td align="left" colspan="1" rowspan="1">Increased bioavailability <italic toggle="yes">in vivo</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Booster vaccinations</td><td align="left" colspan="1" rowspan="1">Water soluble, non-immunogenic, low cost production, enhanced shelf life and to easily cross tissue barriers</td></tr><tr><td align="left" colspan="1" rowspan="1">Elicits B and T cell memory responses</td><td align="left" colspan="1" rowspan="1">MHC class I &amp; II T cell epitopes easily identified</td></tr><tr><td align="left" colspan="1" rowspan="1">Sustainable production of antibodies <italic toggle="yes">in vivo</italic></td><td align="left" colspan="1" rowspan="1">Induction of effective CD8 or CD4 T cell responses <italic toggle="yes">in vivo</italic> by targeting immune checkpoint blockade</td></tr><tr><td align="left" colspan="1" rowspan="1">Clinical grade peptides easily synthesized for rapid translation into Phase I/II clinical trials</td><td align="left" colspan="1" rowspan="1">Easy monitoring of T cell responses</td></tr></tbody></table></table-wrap><p>There are currently several mAbs approved for the treatment of cancers that work by targeting different receptors or immune checkpoint. mAbs-targeting immunologic checkpoints and especially the PD-1/PD-L1 axis provided spectacular results in cancer therapy in the recent years [<xref rid="B40" ref-type="bibr">40</xref>]. The disadvantages and limitations of present immunotherapies are summarized in <xref rid="T2" ref-type="table">Table 2</xref>. Highly specific and successful therapeutic mAbs have been developed for many disease indications. There are some disadvantages to antibody drugs, such as production cost, stability and immunogenicity. Humanized mAbs approved for treatment of several cancers are fraught with a number of concerns. Antibody-based immunotherapies have several limitations such as high production cost of the antibodies. Treatment is expensive and has a limited duration of action, necessitating repeated administrations of the mAb. The half-life of IgG administered intravenously can range from 5 to 21 days. Thus, repeated treatments are necessary; patients typically receive the mAb every week to 3 weeks. The repeated treatment with mAb raises the cost of passive immunotherapy with this mAb to US$150,000 a year. Small molecules have begun to grow into another important treatment modality in this field, and have become an active research field in the cancer drug discovery in addition to antibodies, engineered cells and vaccines [<xref rid="B41" ref-type="bibr">41</xref>].</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.<x xml:space="preserve">&#160;</x></label><caption><title>Disadvantages and Limitations of Present Immunotherapies.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">Humannized mAbs</th><th align="left" colspan="1" rowspan="1">Peptide therapeutics/T-cell vaccines</th><th align="left" colspan="1" rowspan="1">Small molecule RTKs</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Poor penetration across tissues</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">In vivo</italic> instability, short half-life</td><td align="left" colspan="1" rowspan="1">Highly toxic, non-specific activity</td></tr><tr><td align="left" colspan="1" rowspan="1">Ineffective tumor targeting</td><td align="left" colspan="1" rowspan="1">Low bioavailability, susceptibility to proteases, formulation and manufacturing challenges</td><td align="left" colspan="1" rowspan="1">Serious side effects</td></tr><tr><td align="left" colspan="1" rowspan="1">Half life 12 days &#8211; requires weekly infusion</td><td align="left" colspan="1" rowspan="1">Class I MHC restriction limits relevance of individual peptides to certain HLA types</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Large quantities of hmAbs resulting intoxicity</td><td align="left" colspan="1" rowspan="1">Peptides with low affinity for MHC may be poorly immunogenic</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment is very expensive</td><td align="left" colspan="1" rowspan="1">Immune responses transient and/or of low magnitude</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Cross-linking leads potential</td><td align="left" colspan="1" rowspan="1">Large number of peptides required to be useful across a wide range of patients</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Immunogenicity</td><td align="left" colspan="1" rowspan="1">Short peptides may bind directly to MHC which may induce tolerance</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Cardiotoxicity, GI perforation</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">No immunological memory</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment not a cure</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Resistance to targeted therapies</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr></tbody></table><table-wrap-foot><fn><p>GI: Gastrointestinal; mAb: Monoclonal antibodies; RTK: Receptor tyrosine kinase.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0005"><title>Neoantigens: the new kid on the block</title><p>Recently, attention has shifted to neoantigens. Targeting an individual&#8217;s tumor-specific mutations is attractive because these peptides are new to the immune system and are not found in normal tissues. Compared with tumor-associated self-antigens, neoantigens elicit T-cell responses not subject to host central tolerance in the thymus and also produce fewer toxicities arising from autoimmune reactions to nonmalignant cells. Tumor-specific neoantigens are aggressively being explored as targets for personalized cancer vaccines. It has been reported that high mutational loads are strongly associated with increased tumor antigenicity (or immunogenic neoantigens) as well as high frequency of tumor-infiltrating lymphocytes such as CD8<sup>+</sup> T cells. More recently, however, attention has shifted to neoantigens and the identification of neoepitopes to develop cancer vaccines has been suggested to hold great promise, but they have serious misgivings. It is a major challenge to develop cancer vaccines to neoantigens [<xref rid="B42" ref-type="bibr">42</xref>]. The promise, progress and challenges for improving neoantigen-targeted T-cell immunotherapies for cancer are discussed by Yamamoto <italic toggle="yes">et al.</italic> [<xref rid="B43" ref-type="bibr">43</xref>].</p></sec><sec id="S0006"><title>Immunotherapy makes a comeback: immune checkpoint blockade</title><p>Current enthusiasm about cancer immunotherapy stems from the success of some agents targeting immune checkpoint molecules such as PD-1 and CTLA-4 [<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>]. Recent advances in cancer immunology have documented the importance of T-cell-mediated antitumor immunity against human cancers, and inhibitory receptors expressed by T cells have become important targets for cancer immunotherapy. The development of humanized mAbs to checkpoint proteins to inhibit the suppressive effects on T-cell activity has provided the ability to induce prolonged remission in some patients with incurable solid and hematologic malignancies. Checkpoint inhibitor blockade with antibodies specific for CTLA-4 or PD-1 has shown remarkable clinical success in the treatment of cancer and demonstrated impressive activity across a broad set of cancer subtypes, even at advanced and metastatic stages of disease. While mAbs to CTLA-4 and PD-1/PD-L1 have produced remarkable and durable responses in a subset of patients, the majority of patients between 70 and 80% patients receiving anti-PD-1 therapy (nivolumab/pembrolizumab) remain resistant to monotherapy due to the complexity of resistance mechanisms and will not respond or will relapse, leaving a substantial unmet medical need. A plethora of reviews are available that summarizes the impact of checkpoint inhibitors on cancer vaccines which has now commandeered the oncology field [<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>]. With complex mechanisms of resistance limiting the efficacy of checkpoint inhibitor monotherapy, it is critical to develop combination approaches to allow more patients to benefit from immunotherapy.</p></sec></sec><sec disp-level="2" id="S0007"><title>HER-2 is an attractive target for immunotherapy</title><p>HER-2 is a 185-kDa protein and a member of the HER family of RTKs that includes EGFR (EGF receptor, erbB1), HER-3 (erbB3) and HER-4 (erbB4). HER-2 plays a major coordinating role in this network, since each receptor with a specific ligand seems to prefer HER-2 as its heterodimeric partner [<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>]. HER-2 containing heterodimers potently amplify signaling because HER-2 reduces the rate of ligand dissociation, allowing strong and prolonged activation of downstream signaling pathways [<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>], regulating cell growth and differentiation. This receptor plays a central role in the pathogenesis of several human cancers including breast, ovarian, renal, colon and lung carcinomas [<xref rid="B52" ref-type="bibr">52&#8211;56</xref>]. When overexpressed or mutated HER-2 forms homo- and hetero-dimers with other members of the EGFR family that results in the transduction of positive growth signals in a ligand-independent manner. HER-2 is amplified and overexpressed in about 20&#8211;30% of invasive breast cancers and overexpression is associated with aggressive disease and poor prognosis [<xref rid="B57" ref-type="bibr">57</xref>]. Thus, HER-2 is an attractive target for receptor-directed antitumor therapy.</p><p>Breast cancer is one of the leading causes of death around the world. In 2020, it is estimated by the American Cancer Society that 276,430 women will be diagnosed with breast cancer and 42,170 people will die as the consequence of this disease. The treatment landscape for MBC for HER-2-positive patients have a diverse number of regimens pioneered by use of humanized mAbs, mostly targeting RTKs such as the EGFRs (ErbB) and VEGF receptor (VEGFR) [<xref rid="B58" ref-type="bibr">58&#8211;67</xref>]. HER-2 overexpressing breast cancer represents about 20&#8211;30% of all breast cancer cases and is associated with markedly aggressive forms of cancer with a worse prognosis [<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B68" ref-type="bibr">68&#8211;70</xref>].</p></sec><sec id="S0008"><title>HER-2 B-cell epitope peptide vaccines approaches: preclinical &amp; clinical</title><p>Over the past two decades, we have been developing novel combination HER-2 peptide vaccines [<xref rid="B71" ref-type="bibr">71&#8211;74</xref>] that are safe, tolerable and efficacious. Extensive preclinical data conducted over two decades in our labs have established the strategy of engineering conformational B-cell epitope vaccines [<xref rid="B75" ref-type="bibr">75&#8211;78</xref>], designed to stimulate a patient&#8217;s immune system to produce its own antibodies (natural) to a known and validated target for cancer such as RTK receptors. Our chimeric B-cell vaccines incorporating &#8216;promiscuous&#8217; T-cell epitopes [<xref rid="B79" ref-type="bibr">79</xref>,<xref rid="B80" ref-type="bibr">80</xref>], unlike T-cell vaccines can be used for all patient types irrespective of their &#8216;haplotypes&#8217; an issue that impacts T-cell vaccines. Additionally, B-cell vaccines unlike T-cell vaccines are not dependent on inhibiting checkpoint inhibitors to enhance immune responses. The ensuing polyclonal Abs produce a more powerful antitumor effect that is long lasting and inhibits tumor recurrence.</p><sec id="S0009"><title>Prediction of B-cell epitopes &amp; computer-assisted approaches to rational design of peptide vaccines</title><p>The selection of candidate B-cell epitopes expressed on the surface of a known protein sequence can be accomplished by an in-house (Peptide Companion&#8482;, 5x.com) computer-aided analysis using six correlates of antigenicity reviewed by Kaumaya <italic toggle="yes">et al.</italic> [<xref rid="B81" ref-type="bibr">81</xref>]: The profiles of chain flexibility and mobility (Karplus and Schultz) [<xref rid="B82" ref-type="bibr">82</xref>]; hydropathy profiles (Kyte and Doolittle) [<xref rid="B83" ref-type="bibr">83</xref>]; hydrophilicity (Hopp and Woods) [<xref rid="B84" ref-type="bibr">84</xref>]; analysis of solvent exposure algorithm of Rose <italic toggle="yes">et al.</italic> [<xref rid="B85" ref-type="bibr">85</xref>]; protrusion indices (Thornton <italic toggle="yes">et al.</italic>) [<xref rid="B86" ref-type="bibr">86</xref>]; antigenicity (Welling <italic toggle="yes">et al.</italic>) [<xref rid="B87" ref-type="bibr">87</xref>]. The best scoring epitopes were further ranked by correlation with their secondary structural attributes; for example, an amphiphilic &#945;-helical sequence or a &#946;-turn loop regions are preferred over a random coil fragments. Computer programs by Chou and Fasman [<xref rid="B88" ref-type="bibr">88</xref>] and Novotny <italic toggle="yes">et al.</italic> [<xref rid="B89" ref-type="bibr">89</xref>] were used to predict the secondary structure (&#945;-helix, &#946;-strand/sheet, &#946;-turn/loop, random coil) and &#945;-helical amphiphilic moment. Finally, consideration was given to the individual amino acid sequence. Electrostatic ion pairs and helix dipole interaction in helical segment were also considered (e.g., hydrophobic/hydrophilic balance).</p><p>The recent advancements in the technological and bioinformatics fields enable computer-based approaches for prediction bioinformatics tools for epitope prediction [<xref rid="B90" ref-type="bibr">90</xref>]; A range of computational methods have been developed for predicting which of an antigen&#8217;s residues are likely to form part of a B-cell epitope: computational prediction of vaccine potential epitopes and 3D structure [<xref rid="B91" ref-type="bibr">91</xref>]; an analysis of B-cell epitope discontinuity [<xref rid="B92" ref-type="bibr">92</xref>], B-cell epitope identification and production of neutralizing murine antibodies [<xref rid="B93" ref-type="bibr">93</xref>]; structural analysis of B-cell epitopes in antibody:protein complexes [<xref rid="B94" ref-type="bibr">94</xref>]. <italic toggle="yes">In silico</italic> peptide development approaches to predict B-cell epitope online analysis resource at IEDB (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.iedb.org/">www.iedb.org/</ext-link>) and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://tools.immuneepitope.org/toolsElliPro/">http://tools.immuneepitope.org/toolsElliPro/</ext-link>.</p></sec><sec id="S0010"><title>Identification of HER-2 B-cell epitopes as potential vaccine candidates</title><p>Eight B-cell epitopes of HER-2 extracellular domain (ECD) were identified by antigenicity predictive algorithms (reviewed by Kaumaya <italic toggle="yes">et al.</italic> [<xref rid="B81" ref-type="bibr">81</xref>] in 2000). These peptide B-cell sequences were engineered with a measles virus fusion protein (MVF, amino acids 288&#8211;302) &#8216;promiscuous&#8217; T-cell epitope as potential chimeric vaccines. A series of <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies identified two epitopes HER-2 (628&#8211;647) and HER-2 (316&#8211;339) [<xref rid="B71" ref-type="bibr">71</xref>,<xref rid="B72" ref-type="bibr">72</xref>] as viable vaccines. MVF-HER-2 (628&#8211;647) elicited exceptionally high antibody titers that bind the native HER-2 protein as assessed by immunoprecipitation, flow cytometry and indirect ELISA and <italic toggle="yes">in vivo</italic> studies in transgenic mice demonstrated that the 628&#8211;647 epitope had the highest activity by eliciting antibodies able to cause ADCC as measured by lysing overexpressing cell lines BT474 and SKBR3. The vaccine was effective in preventing mammary tumors [<xref rid="B71" ref-type="bibr">71</xref>] in proto-oncogene (NEU) transgenic mice. Similarly, the MVF-316-339 elicited high-specific antibodies to the native HER-2 that caused inhibition of phosphorylation. The most effective combination vaccine HER-2 sequences 316&#8211;339 and 628&#8211;647 [<xref rid="B72" ref-type="bibr">72</xref>] elicited the highest titers and also caused the highest receptor downmodulation, similar to that produced by the control antibody HER-2 mAb L26, able induce a higher amount of IFN-&#947; in the presence of effector human peripheral blood mononuclear cell (PBMCs) compared with single epitope vaccines. The efficacy of the combo vaccine was shown by <italic toggle="yes">in vivo</italic> tumor protection in a BALB/c syngeneic model challenged with human HER-2 (RENCA/<italic toggle="yes">lacZ</italic>/HER-2). The most effective combination vaccine was found to be identified entirely serendipitously through our peptide strategy. It turns out later that these two sequences overlapped the pertuzumab- and trastuzumab-binding sites of HER-2. We initiated a Phase I clinical trial with a combination of these two peptides in 2002 at the Ohio State University Comprehensive Cancer Center.</p></sec><sec id="S0011"><title>Other B-cell epitope peptide HER-2 vaccines</title><p>In 2003, the Wiedermann group in Vienna was also developing HER-2 peptide-based vaccines in similar fashion by computer-aided analyses that identified seven putative B-cell epitopes of HER-2 [<xref rid="B95" ref-type="bibr">95</xref>]. These peptide epitopes were coupled to tetanus toxoid and used for immunization in BALB/c mice. Among these peptides, immunizations with two single peptides or a combination of two peptides induced antipeptide antibody levels, primarily of the IgG1 isotype. It was confirmed that immunization with HER-2 peptides successfully induced humoral immune response with antitumor activity in an animal model. A Phase I clinical trial with an anti-HER-2 vaccine-construct of immune-potentiating reconstituted influenza virosomes with the three peptides in patients with MBC [<xref rid="B96" ref-type="bibr">96</xref>]. The HER-2 multipeptide vaccine was safe, well tolerated and effective in overcoming immunological tolerance to HER-2. More recently, Wiedermann group developed a new vaccine: three short single peptides (P4, P6 and P7) representing different HER-2 ECD B-cell epitopes fused as a single hybrid peptide P467 on either virosomes or to diphtheria toxoid CRM197 (CRM) [<xref rid="B97" ref-type="bibr">97</xref>]. The formulation P467-CRM-Montanide induced higher serum IgG antibody titers, compared with P467-CRM-Alum. Fusion of the B-cell peptides has led to additional generation of CD4 T-cell epitopes, and this P467-multiepitope vaccine was found to induce polyclonal antibody responses with antiproliferative capacity against Her-2/neu. The hybrid vaccine together with Montanide induced higher and long-lasting antibody levels, Th1-biased cellular responses being superior to vaccination with the single B-cell peptides. This vaccine formulation is now planned to be evaluated in a Phase Ib/II study in HER-2 overexpressing cancer patients (IMU-131 [HerVaxx]). Another group led by Mahdavi and colleagues [<xref rid="B98" ref-type="bibr">98</xref>] has also designed a discontinuous chimeric peptide representing B- and T-cell epitopes from subdomain III of HER-2-ECD following design principles we have advanced. The author&#8217;s claim their findings can be applied for mAb production targeting the distinct epitope of HER-2 receptor compared with the two broadly used anti-HER-2 mAbs, Herceptin and Perjeta.</p></sec><sec id="S0012"><title>Other B-cell epitope approaches targeting VEGF &amp; EGFR</title><sec id="S0013"><title>VEGF B-cell vaccine</title><p>Wentink and colleagues [<xref rid="B99" ref-type="bibr">99</xref>] designed 3D-structured peptide mimicking the VEGF &#946;5-turn-&#946;6 loop-binding site of bevacizumab-elicited neutralizing antipeptide antibodies. Similar to our work in designing conformational VEGF vaccine, VEGF peptide mimics as well as combination VEGF + HER-2 vaccine by Kaumaya <italic toggle="yes">et al.</italic> [<xref rid="B100" ref-type="bibr">100&#8211;103</xref>], they demonstrated that structured B-cell epitope vaccine was superior to the linear unstructured peptides. This work is an independent proof and confirmation that B-cell epitope-based vaccines are often required to elicit high affinity polyclonal antibodies that are efficacious <italic toggle="yes">in vivo</italic>. This vaccine is currently being investigated in a Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02237638">NCT02237638</ext-link>) to demonstrate the potential to outperform anti-VEGF treatment strategies.</p></sec><sec id="S0014"><title>EGFR-based vaccine</title><p>Using a mimotope approach, two peptides were identified and epitope-specific immunization has produced an effective anti-EGFR immunotherapy that can elicit the production of &#8216;cetuximab-like&#8217; antibodies <italic toggle="yes">in vivo</italic> [<xref rid="B104" ref-type="bibr">104</xref>]. The two peptides are capable of mimicking the conformational structure of EGFR-panitumumab-binding sites inducing both humoral and cellular immune responses against EGFR, could serve as candidate vaccines for active immunotherapy against EGFR-positive cancers. Zhu <italic toggle="yes">et al.</italic> [<xref rid="B105" ref-type="bibr">105</xref>] targeting the dimer interface of EGFR in patients synthesized a chimeric peptide, comprising a linear B-cell epitope peptide from the highly conservative &#946;-hairpin loop of dimer interface of human EGFR (EGFR 237&#8211;267) and a &#8216;promiscuous&#8217; Th-cell epitope MVF from the MVF protein. These peptides were highly immunogenic, stimulated high production of antibodies in animal models, and significantly inhibited tumor growth in patients. The chimeric peptide immunization was able to significantly inhibit the growth of subcutaneously transplanted LLC cells in C57BL6 mice. Therefore, the MVF-EGFR 237&#8211;267 construct represents a promising candidate for active anti-EGFR immunotherapy and provides a novel targeting strategy for the anti-EGFR therapy.</p></sec><sec id="S0015"><title>CIMAvax-EGF vaccine</title><p>Another group led by Garcia and colleagues in Cuba has designed EGF-based cancer vaccine (CIMAvax EGF<sup>&#174;</sup>) conjugate of human recombinant EGF with the P64K protein of <italic toggle="yes">Neisseria meningitides</italic> (acting as a carrier protein) [<xref rid="B106" ref-type="bibr">106</xref>]. The vaccine was designed to induce specific anti-EGF antibodies with the Montanide ISA 51, as adjuvant. The vaccine induced antibodies against EGF that results in EGF withdrawal. CIMAvax-EGF has been demonstrated to be safe and immunogenic in advanced non-small-cell lung cancer (NSCLC) patients (reviewed by Saavedra and colleagues [<xref rid="B107" ref-type="bibr">107</xref>]). CIMAvax-EGF vaccine is an innovative immunotherapy that exerts its anticancer activity by inducing a B-cell response. Through an historic partnership with Cuba&#8217;s Centro de Inmunolog&#237;a Molecular, or CIM, Roswell Park is helping to develop several innovative and potentially life-saving cancer therapies. The first of these new approaches to be available to US patients is CIMAvax-EGF, an immunotherapy for lung cancer.</p><p>Several clinical trial are ongoing to explore the combination of CIMAvax and anti-PD-1 antibodies. Final results from the first US clinical study of a Cuban immunotherapy show that CIMAvax-EGF, a treatment targeting a particular cancer survival protein, EGF, is safe and showed promising efficacy as part of a treatment combination with nivolumab (Opdivo) in patients with advanced NSCLC. The team reports that the combination of these two immunotherapies was safe and well tolerated. They observed promising efficacy in patients whose tumors have low PD-L1 expression and who would not, therefore, be likely to respond well to nivolumab alone. A Phase II study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02955290">NCT02955290</ext-link>) is ongoing at Roswell Park, NY, USA, now expanded to include two additional groups of participants as well as those with recurrent NSCLC: Patients with advanced, recurrent squamous-cell head and neck cancer, who will receive the CIMAvax-nivolumab combination. Patients with advanced NSCLC evidencing high PD-L1 levels, who will receive CIMAvax in combination with pembrolizumab (Keytruda<sup>&#174;</sup>) as first-line or initial treatment for NSCLC. Nearly $4 million in donations is funding Roswell Park&#8217;s initial CIMAvax clinical trials. These studies are being conducted in collaboration with scientists from the CIM in Havana, Cuba, and innovative Immunotherapy Alliance, an historic biotech venture formed by Roswell Park and the CIM.</p></sec><sec id="S0016"><title>From bench to clinic: first-generation HER-2 B-cell epitope Phase I clinical trial</title><p>An NCI-funded (CA84356), OSU cancer IRB approved (2001C0108) and FDA approved (BB-IND-9803) Phase I clinical trial with a combination of two HER-2 Chimeric B-cell MVF 316&#8211;339 epitopes and MVF 628&#8211;647 (<xref ref-type="fig" rid="F1">Figure 1</xref>) [<xref rid="B108" ref-type="bibr">108&#8211;111</xref>] emulsified with nor-MDP as adjuvant and ISA 720 vehicle successfully completed at the James Cancer Hospital. The trial evaluated the maximum-tolerated dose, safety profile and immunogenicity. Eligible patients with metastatic and/or recurrent solid tumors received three inoculations on days 1, 22 and 43 at doses of total peptide that ranged from 0.5 to 3.0 mg. 24 patients received three inoculations at the intended dose levels, which elicited antibodies able to recognize native HER-2 receptor and inhibited both the proliferation of HER-2-expressing cell lines and phosphorylation of the HER-2 protein. The maximum-tolerated dose was determined to be the highest dose level of 3.0 mg of the combination vaccine. There was a significant increase from dose level 1 (0.5 mg) to dose level 4 (3.0 mg) in HER-2-specific antibodies. Four patients (one each with adrenal, colon, ovarian and squamous cell carcinoma of unknown primary) were judged to have SD; two patients (one each with endometrial and ovarian cancer) had partial responses; and 11 patients had progressive disease. Patients with SD received 6-month boosts, and one patient received a 20-month boost. The combination vaccines were safe and effective in eliciting antibody responses in a subset of patients (62.5%) and were associated with no serious adverse events, autoimmune disease or cardiotoxicity. There was preliminary evidence of clinical activity in several patients.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1.<x xml:space="preserve">&#160;</x></label><caption><title>Preclinical second-generation conformational HER-2 peptides mimicking trastuzumab and pertuzumab-binding sites.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fon-16-1767-g1.jpg"/></fig></sec></sec></sec><sec id="S0017"><title>Peptide vaccine HER-2-binding sites</title><sec id="S0018"><title>Preclinical second-generation conformational HER-2 peptides mimicking trastuzumab- and pertuzumab-binding sites</title><p>The x-ray structures of the HER-2-trastuzumab and -pertuzumab complexes [<xref rid="B109" ref-type="bibr">109&#8211;111</xref>] have led us to rationally design more effective HER-2 conformational epitope vaccines such as the trastuzumab-binding epitope (597&#8211;626) and the pertuzumab-binding epitope (266&#8211;296; <xref ref-type="fig" rid="F1">Figure 1</xref>) [<xref rid="B112" ref-type="bibr">112</xref>] with potentially increased efficacy for preventing and inhibiting tumor growth.</p><sec id="S0019"><title>Trastuzumab-binding conformational B-cell epitope</title><p>The 3D structure of the complex between human HER-2 and trastuzumab revealed that the region of HER-2-spaning residues 563&#8211;626 of the antigen-binding domain harbors a complex disulfide bonding pattern [<xref rid="B109" ref-type="bibr">109</xref>,<xref rid="B110" ref-type="bibr">110</xref>]. The structure of soluble HER-2-trastuzumab Fab complex showed that the trastuzumab-binding region is located on the C-terminus of the HER-2 ECD domain IV and this complex buries 1350 &#197;<sup>2</sup> of the HER-2 surface with three loops residues 579&#8211;583, 615&#8211;625 and 592&#8211;595. In order to minimally dissect the interacting region of HER-2 binding domain, four synthetic peptides having with different levels of structural flexibility were designed and synthesized (<xref rid="B75" ref-type="bibr">75</xref>). The interacting loops in subdomain IV comprise residues in <bold>loop 1</bold>: 579&#8211;583 (two disulfide pairings between C563&#8211;C576, and between C567&#8211;C584), <bold>loop 2</bold>: 592&#8211;595 (cysteine disulfide pairing between C587&#8211;C596) and <bold>loop 3</bold>: 615&#8211;625 (cysteine disulfide between C600&#8211;C623). Chimeric peptides incorporating the MVF &#8216;promiscuous&#8217; T-cell epitope via a four-residue linker sequence were synthesized, purified and characterized. All conformationally restricted peptides were recognized by trastuzumab and prevented the function of trastuzumab-inhibiting tumor cell proliferation, with 563&#8211;598 and 597&#8211;626 showing greater reactivity. All epitopes were immunogenic in FVB/n mice with antibodies against 597&#8211;626 and 613&#8211;626 recognizing HER-2. The 597&#8211;626 epitope was immunogenic in outbred rabbits eliciting antibodies which recognized HER-2, competed with trastuzumab for the same epitope, inhibited proliferation of HER-2-expressing breast cancer cells <italic toggle="yes">in vitro</italic> and caused their ADCC. Moreover, immunization with the 597&#8211;626 epitope significantly reduced tumor burden in transgenic BALB-<italic toggle="yes">neu</italic>T mice. Thus, the trastuzumab-like MVF-597&#8211;626 epitope can be included in a combination therapy with the pertuzumab-like MVF266&#8211;296 epitope.</p></sec><sec id="S0020"><title>Pertuzumab-binding conformational B-cell epitopes</title><p>The crystal structure of pertuzumab bound to the ECD of HER-2 elucidated the details of interacting region of residues 266&#8211;333 [<xref rid="B111" ref-type="bibr">111</xref>]. This structure provides a model in which pertuzumab sterically interferes with HER-2 dimerizing with other members of the HER family. We designed and studied the important binding sequences spanning residues 266&#8211;296, 298&#8211;333 and 315&#8211;333 to define the most biologically relevant conformational epitope that mimic the pertuzumab-binding conformational region for effective vaccination. We designed three conformational peptide constructs to mimic regions of the dimerization loop of the receptor and to characterize the <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> antitumor efficacy. Chimeric peptides incorporating the MVF &#8216;promiscuous&#8217; T-cell epitope via a four-residue linker sequence were synthesized, purified and characterized [<xref rid="B111" ref-type="bibr">111</xref>]. All the constructs elicited high affinity antipeptide antibodies and all the antipeptide antibodies showed ADCC to varying degrees with the 266&#8211;296 constructs being equally effective as compared with trastuzumab. The MVF-266&#8211;296 elicited high-specific antibodies to the native HER-2 that caused inhibition of phosphorylation. The 266&#8211;296 peptide vaccine statistically reduced tumor onset in both transplantable tumor models (FVB/n and BALB/c) and significant reduction in tumor development in a transgenic mouse tumor model (Balb-<italic toggle="yes">neu</italic>T) confirming its validity to be included in a combination immunotherapy to be tested in a Phase I trial [<xref rid="B113" ref-type="bibr">113</xref>].</p><p>IND #14633 (Kaumaya); NIH CA18902; Phase I active immunotherapy trial with a combination of two chimeric HER-2 B-cell peptide vaccine MVF-HER-2 (597&#8211;626; <italic toggle="yes">trastuzumab-like</italic>) and MVF-HER-2 (266&#8211;296; pertuzumab-like) emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumors. Patients were immunized with the vaccine constructs emulsified with nor-muramyl-dipeptide adjuvant in a water-in-oil Montanide ISA 720VG vehicle (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2.<x xml:space="preserve">&#160;</x></label><caption><title>Vaccination and Dose levels.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fon-16-1767-g2.jpg"/></fig><p>Eligible patients with metastatic and/or recurrent solid tumors received three inoculations every 3 weeks. The trial is a dose-escalating study consisting of four cohorts of six patients. Of the 49 patients with metastatic and/or recurrent solid tumors with a median of four prior lines of chemotherapy, only 28 patients completed the three vaccination regimens. No serious adverse reactions or dose-limiting toxicities were observed. The vaccine was well tolerated with dose level 2 as the recommended Phase II dose. The most common related toxicities in all patients were injection site reactions (24%). Two patients had a partial response, 14 had stable disease (SD) and 19 had progressive disease. Six patients received one 6-month boost, with one patient receiving as much as seven 6-month boosts. The study vaccine was safe, exhibited antitumor activity and showed preliminary indication that peptide vaccination may avoid therapeutic resistance and offer a promising alternative to mAb therapies. Given the initial promise, continuous development of the vaccine is ongoing in a Phase II trial at the suggested optimal biological dose (OBD) in a less heavily pretreated patient population in breast and/or gastrointestinal malignancies with HER-2/EGFR overexpression. The clinical data are summarized in the waterfall (<xref ref-type="fig" rid="F3">Figure 3</xref>). One HER-2-positive patient received seven 6-monthly booster vaccinations suggesting that B-cell vaccination does not result in resistance to therapy as is well documented for other HER-2 therapies. A majority of the patient antibodies showed potent antitumor activity (induction of ADCC and apoptosis, inhibition of proliferation and phosphorylation).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3.<x xml:space="preserve">&#160;</x></label><caption><title>Phase I clinical trial HER-2 combination vaccine (B-Vaxx).</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fon-16-1767-g3.jpg"/></fig><p>While Herceptin and Perjeta have been approved for clinical use, patients often develop resistance to these therapies. This study of the combination of the two HER-2 B-cell peptide vaccines to safely deliver curative and transformative cancer immunotherapies to advanced cancer patients is a validation of the effectiveness of B-cell immunotherapy strategies. This is a new paradigm in immunotherapy that focuses on humoral responses based on vaccination with conformational B-cell epitope vaccines comprising two chimeric HER-2 B-cell peptide vaccines incorporating a &#8216;promiscuous T-cell epitope.&#8217;</p><p>The vaccine works in innovative ways (<xref ref-type="fig" rid="F4">Figure 4</xref>) in which the peptide vaccine is given intramuscularly at 3 weeks interval. The T-cell epitope of the chimeric construct binds MHC class II directly without processing activating the T cell with cytokine release that helps the B cell to produce natural polyclonal antibodies that can bind the tumor cell.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4.<x xml:space="preserve">&#160;</x></label><caption><title>The B-cell epitope peptide vaccine works in innovative ways.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fon-16-1767-g4.jpg"/></fig></sec></sec><sec id="S0021"><title>Other HER-2 clinical trials</title><p>Clinical trial <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02795988">NCT02795988</ext-link>: A study of IMU-131 (HER-Vaxx) and chemotherapy compared with chemotherapy only in patients with HER-2-positive advanced gastric cancer. Imugene Ltd, an Australian immuno-oncology company announced comprehensive clinical data results from the Phase Ib clinical study of its HER-Vaxx anticancer vaccine in gastric cancer patients overexpressing HER-2 target protein. Imugene Ltd&#8217;s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumors that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This small study&#8217;s data in 68 patients showed a 100% objective response rate in three patients who received the optimal dose of 50 &#956;g.</p><p>Clinical trial <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02795988">NCT02795988</ext-link></italic>: A study of IMU-131 (HER-Vaxx) and chemotherapy compared with chemotherapy only in patients with HER-2-positive advanced gastric cancer. The Phase Ib study aims to determine the safety and tolerability of IMU-131 and identify the Recommended Phase II Dose of IMU-131 in combination with chemotherapy in HER-2/neu overexpressing ACS to carry into the Phase II dose-expansion study. The Phase II component is presently ongoing. Phase II will be designed to further characterize the safety and to explore clinical activity of IMU-131 in combination with chemotherapy in HER-2/neu overexpressing ACS. The Phase II study is a randomized, open-label comparison of IMU-131 plus standard of care chemotherapy versus standard of care chemotherapy alone.</p><sec id="S0022"><title>Mechanisms of resistance to HER-2-targeted therapy</title><p>Cross-talk and compensatory signaling networks limit the activity of most targeted therapies, including HER-2-targeted agents. Multiple mechanisms of trastuzumab resistance have been proposed by Peake and Nahta [<xref rid="B114" ref-type="bibr">114</xref>]. The mechanisms through which trastuzumab blocks tumor growth include reduced downstream signaling, inhibition of angiogenesis and increased immune activity, primarily ADCC [<xref rid="B115" ref-type="bibr">115</xref>]. Other proposed mechanisms include Inhibition of homo- or hetero-dimerization, receptor downregulation through endocytosis, upregulation of HER-2 downstream signaling pathway. Signaling through an alternate receptor pathway, and failure to trigger immune-mediated mechanisms to destroy tumor cells.</p><p>The signaling networks consisting of IGF-1R, EGFR/HER-1, HER-2 and HER-3 play major roles in trastuzumab resistance [<xref rid="B116" ref-type="bibr">116&#8211;121</xref>]. Recent evidence also suggests that HER-3 also plays a central role and contributes to escape from therapeutic suppression by several tyrosine kinase inhibitors in breast cancer [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B122" ref-type="bibr">122</xref>,<xref rid="B123" ref-type="bibr">123</xref>]. HER-3 has also been shown to be involved in acquired resistance to HER-2-targeted therapies and other inhibitors that directly or indirectly antagonize PI3K signaling [<xref rid="B124" ref-type="bibr">124</xref>,<xref rid="B125" ref-type="bibr">125</xref>]. Trastuzumab has been shown to be mediated by increased HER-3 signaling in part due to heterodimerization of HER-2 and HER-3 that is critical for the growth and progression of HER-2-positive breast cancers [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B122" ref-type="bibr">122</xref>,<xref rid="B123" ref-type="bibr">123</xref>,<xref rid="B126" ref-type="bibr">126</xref>,<xref rid="B127" ref-type="bibr">127</xref>], or HER-2 and IG-1R and in part through the formation of heterotrimers involving HER-2, HER-3 and IGF-1R [<xref rid="B117" ref-type="bibr">117</xref>]. Increased expression of IGF-1R also reduces the growth inhibitory activity of trastuzumab [<xref rid="B119" ref-type="bibr">119</xref>]. The formation of a unique receptor complex containing IGF-1R and HER-2 in resistant cells facilitates cross-talk from IGF-1R to HER-2, resulting in sustained HER-2 phosphorylation in resistant cells [<xref rid="B117" ref-type="bibr">117</xref>,<xref rid="B121" ref-type="bibr">121</xref>,<xref rid="B128" ref-type="bibr">128</xref>].</p><p>Therapeutic strategies that target single molecular pathways eventually succumb to problems of intrinsic or acquired resistance due to extensive signaling &#8216;cross-talk.&#8217; Targeting two or more receptors have the potentials to inhibit cross-talk and development of resistance that occurs in single treatment. For these reasons, we have targeted multiple signaling pathways that can offer hope, circumvent resistance mechanisms, provide synergy and enhance tumor effects. The combination of different vaccine and therapeutic strategies to target specific molecular pathways that are dysregulated in tumors may create clinical breakthroughs for safe and efficacious cancer cures.</p><p>The EGF receptors (HER-1, HER-2, HER-3 and HER-4), VEGF receptor (VEGFR) [<xref rid="B58" ref-type="bibr">58&#8211;67</xref>,<xref rid="B129" ref-type="bibr">129</xref>,<xref rid="B130" ref-type="bibr">130</xref>] and IGF receptor-1 (IGF-1R) [<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B132" ref-type="bibr">132</xref>] are members among RTKs. A plethora of FDA-approved agents targeted against RTK signaling pathways [<xref rid="B19" ref-type="bibr">19&#8211;21</xref>] are directed against HER-2 (trastuzumab, pertuzumab, lapatinib, Kadcyla [T-DM1] and Fam-trastuzumab deruxtecan-nxki), EGFR (cetuximab, gefitinib, erlotonib) or VEGF (bevacizumab, sunitinib). These agents have markedly improved survival but demonstrate significant toxicities [<xref rid="B22" ref-type="bibr">22&#8211;24</xref>].</p><p>We have developed novel approaches such as active immunization against RTKs that offer an alternative and effective treatment options (reviewed by Kaumaya [<xref rid="B2" ref-type="bibr">2</xref>]). The strategies focus on the design of chimeric B- &amp; T-cell novel vaccines to HER-2 [<xref rid="B71" ref-type="bibr">71&#8211;74</xref>], VEGF [<xref rid="B100" ref-type="bibr">100</xref>], EGFR/HER-1 [<xref rid="B133" ref-type="bibr">133</xref>], HER-3 [<xref rid="B134" ref-type="bibr">134</xref>] and IGF-1R [<xref rid="B123" ref-type="bibr">123</xref>,<xref rid="B134" ref-type="bibr">134</xref>] specifically aimed at eliciting specific high affinity antibodies (B cell). Recently, we have also developed novel VEGF strategies and combination HER-2/VEGF [<xref rid="B135" ref-type="bibr">135</xref>,<xref rid="B136" ref-type="bibr">136</xref>]. We have identified crucial peptides that target <italic toggle="yes">HER-1, HER-2, HER-3 and IGF-1R</italic>; these peptides effectively reduce tumor growth in xenograft models of cancer. We have identified and validated the most effective combinations of EGFR (HER-1), HER-2, HER-3 and IGF-1R peptide vaccines/mimics to selectively inhibit multiple signaling pathways in rigorous <italic toggle="yes">in vitro</italic> studies.</p><p>Having established a portfolio (<xref ref-type="fig" rid="F5">Figure 5</xref>) of validated peptide epitopes as either vaccine candidates or peptide mimics, we have initiated a series of combination therapies to determine <italic toggle="yes">in vitro</italic> antitumor effects prior to verifying their efficacy <italic toggle="yes">in vivo</italic> in animal models. Ultimately, our goal was to identify the most biologically effective combinations of EGFR (HER-1), HER-2, HER-3 and/or IGF-1R peptide vaccines to selectively inhibit multiple receptors and signaling pathways to overcome the extensive receptor cross-talk that drives the biology and resistance of HER-overexpressing cancers. Optimal combinations of anti-HER-2 agents delivered with anyone of the following other growth factors such as HER-1, HER-3, VEGF and IGF-1R may provide the best therapy for breast cancers and other solid tumors including pancreatic, colon, gastrointestinal stromal tumor (GIST) and lung. This strategy holds the promise of achieving durable cures for multiple types of cancers that can be translated to human clinical trials.</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5.<x xml:space="preserve">&#160;</x></label><caption><title>Peptide B-cell vaccine portfolio.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fon-16-1767-g5.jpg"/></fig><fig id="F6" orientation="portrait" position="float"><label>Figure 6.<x xml:space="preserve">&#160;</x></label><caption><title>Immuno-oncology and B-cell vaccine landscape.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fon-16-1767-g6.jpg"/></fig></sec></sec></sec><sec id="S0023"><title>Combination immunotherapies to overcome resistance to targeted therapies</title><p>We have demonstrated that combination therapies with HER-2 and IGF-1R or HER-2 and HER-3 (BT-474 and JIMT-1) and HER-1 and IGF-1R (TNBC, MDA-MB-231) exhibit enhanced antitumor responses in breast cancer cell lines [<xref rid="B134" ref-type="bibr">134</xref>,<xref rid="B137" ref-type="bibr">137</xref>]:</p><sec id="S0024"><title>HER-2 &amp; IGF-1R in breast cancer</title><p>Resistance toward anti-HER-2 antibodies trastuzumab has been shown to be mediated by increased IGF-1R signaling [<xref rid="B138" ref-type="bibr">138</xref>,<xref rid="B139" ref-type="bibr">139</xref>]. Combination treatment with &#945;-HER-2-(597&#8211;626) and &#945;-IGF-1R-(56&#8211;81) peptide antibodies in trastuzumab-resistant (JIMT-1) and trastuzumab-sensitive (BT-474) human breast cancer cells inhibits proliferation, receptor phosphorylation and significantly induces apoptosis, ADCC and cellular invasion. These results indicate that cotargeting HER-2 and IGF-1R produce significant antitumor effects, synergistically blocks tumor growth of breast cancers and can be used to overcome trastuzumab resistance in breast cancer and points to the potential benefits of dual targeting. Cotargeting HER-2 and IGF-1R produces significant antitumor effects, and potentially overcomes trastuzumab resistance in breast cancer supporting the concept of dual targeting IGF-1R and HER-2 in this setting. Additionally, we also recently showed that combining the IGF-1R-56-81 peptide antibody with HER-2 mAb trastuzumab suppresses invasion and induces ADCC in JIMT-1 trastuzumab-resistant breast cancer cells [<xref rid="B123" ref-type="bibr">123</xref>], further supporting our dual strategy.</p></sec><sec id="S0025"><title>HER-2 &amp; HER-3 in breast cancer</title><p>Dual-specific antibodies against HER-2:HER-3 or EGFR:HER-3 heterodimers are being evaluated [<xref rid="B140" ref-type="bibr">140</xref>,<xref rid="B141" ref-type="bibr">141</xref>], but none have yet been found to be useful. Our results show that combination treatment with HER-2 and HER-3 peptide vaccine antibodies in two different cell lines BT-474 breast cancer cell line and JIMT-1 a trastuzumab-resistant cell line caused an increased rate of inhibition of proliferation versus single treatments. Phosphorylated levels of HER-2 and HER-3 following combined treatment with both HER-2 and HER-3 peptide antibodies caused enhanced inhibition of phosphorylation as compared with individual treatment. Significant inhibition was achieved in the BT-474 breast cancer cell that has high HER-2 and HER-3 overexpression. Overall, the results point to the potential benefits of a combination approach targeting HER-3 and HER-2 in breast, pancreatic and colon cancers. Combination treatment with &#945;-HER-2 and &#945;-HER-3 peptide vaccine antibodies on cancer cell induced apoptosis and caused ADCC.</p><sec id="S0026"><title>HER-1 &amp; HER-2 in colon cancer</title><p>Human colorectal cancer (CRC) is one of the most common malignancies and remains largely incurable. HER-1 and HER-2 are highly implicated in CRCs [<xref rid="B142" ref-type="bibr">142</xref>,<xref rid="B143" ref-type="bibr">143</xref>], and cetuximab, a blocking anti-EGFR mAb, is effective in combination with chemotherapy or as single agent for the treatment of patients with <italic toggle="yes">KRAS</italic> wild-type metastatic CRC [<xref rid="B144" ref-type="bibr">144</xref>,<xref rid="B145" ref-type="bibr">145</xref>]. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug [<xref rid="B146" ref-type="bibr">146</xref>], leading to treatment failure. Combination treatment with anti-HER-1-418 and anti-HER-2-266 peptide vaccine antibodies in Caco-2 cells inhibited cell proliferation, inhibited receptor phosphorylation more than treatment with single-peptide antibody alone, and mediated ADCC using HT-29 colon cancer. Finally, we showed that HER-1 and HER-2 peptide antibodies were capable of inducing apoptosis in Caco-2 cells via a caspase activation assay, inhibited cell proliferation more than single treatment, corroborating our results obtained with the peptide antibodies</p></sec></sec><sec id="S0027"><title>HER-1 in combination with HER-3 or IGF-1R human pancreatic cancer</title><p>An estimated 57,600 new cases of pancreatic cancer (PC) are expected to occur in the USA during 2020 with an estimated 47,050 deaths (American Cancer Society) [<xref rid="B147" ref-type="bibr">147</xref>]. Several studies demonstrate that HER-1 overexpression correlates with poor prognosis and increased metastasis of PCs [<xref rid="B148" ref-type="bibr">148</xref>]. Several recent studies also show that HER-3 is frequently upregulated in cancers with HER-1 (EGFR) overexpression. It is clear that innovative approaches are needed for the prevention and treatment of PC [<xref rid="B149" ref-type="bibr">149</xref>]. IGF-1R has also been implicated in the growth and development of multiple tumor types [<xref rid="B150" ref-type="bibr">150</xref>] and is expressed in 50&#8211;60% of PCs [<xref rid="B151" ref-type="bibr">151</xref>,<xref rid="B152" ref-type="bibr">152</xref>]. The IGF-1R:IGF-1 pathway is implicated in the development of resistance to anticancer drugs [<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B153" ref-type="bibr">153</xref>] as well as in PC [<xref rid="B154" ref-type="bibr">154</xref>]. HER-1 is implicated in aggressive PCs with poor patient outcome [<xref rid="B155" ref-type="bibr">155</xref>,<xref rid="B156" ref-type="bibr">156</xref>] and decrease overall survival [<xref rid="B157" ref-type="bibr">157&#8211;159</xref>]. Increased expression of IGF-1R increases expression of HER-1 and results in the formation of IGF-1R/HER-1 dimers [<xref rid="B160" ref-type="bibr">160</xref>,<xref rid="B161" ref-type="bibr">161</xref>]. There is considerable evidence of cross-talk between <italic toggle="yes">HER-1 and IGF-1R</italic> in PC cells [<xref rid="B162" ref-type="bibr">162</xref>]. In this aim, we will test the hypothesis that either combined inhibition of HER-1 and HER-3 or HER-1 and IGF-1R will enhance the inhibition of tumor growth in xenograft models of <italic toggle="yes">PCs</italic>.</p><sec id="S0028"><title>HER-1 &amp; IGF-1R</title><p>Combination treatment with HER-1-418 and IGF-1R-56 peptide antibodies in BxPC-3 pancreatic cells inhibited proliferation, receptor phosphorylation and significantly induced apoptosis, ADCC and cellular invasion. Previous studies in our laboratory established the HER-1-418 epitope as a novel inhibitor of HER-1-dependent signaling <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> [<xref rid="B163" ref-type="bibr">163</xref>]. These results indicate that cotargeting HER-1 and IGF-1R produces significant antitumor effects and is a promising approach for inhibiting PCs.</p></sec><sec id="S0029"><title>HER-1-418 &amp; HER-3-461</title><p>Combination HER-3-461 + HER-1-418 peptide antibodies caused significant inhibition of proliferation in BxPC3 PC cells and decreased receptor phosphorylation, significantly delayed tumor growth in mice challenged with BxPC3 cells demonstrated synergistic antitumor effects and significantly induced apoptosis and ADCC. Significant apoptosis was observed with HER-3 peptide mimics in BxPC-3 cells; the peptide constructs HER-3 (461&#8211;479). These data provide strong rationale for cotargeting HER-1 and HER-3 in PCs.</p></sec><sec id="S0030"><title>The potential of B-cell peptide cancer vaccines</title><p>Taken together, the work summarized here strongly highlights the potential of B cells for vaccine immunotherapy and their applicability in a clinical setting. In a recent article, Wennhold <italic toggle="yes">et al.</italic> [<xref rid="B164" ref-type="bibr">164</xref>] surmised that it can be expected that the near future will see the first clinical trials of B-cell-based cancer vaccines. Wennhold <italic toggle="yes">et al.</italic> concluded that these trials will show if B cells deserve a place in the oncologist&#8217;s toolbox. We can argue that our work over the past three decades and translation of two HER-2 B-cell vaccine in a Phase I clinical trial in 2009 [<xref rid="B108" ref-type="bibr">108</xref>] and 2019 [<xref rid="B165" ref-type="bibr">165</xref>] is testament to the viability of B-cell cancer vaccines in our armamentarium of IO landscape.</p></sec></sec></sec><sec id="S0031"><title>The promise of IO: development of a novel PD-1 vaccine</title><p>Therapeutic blockade of the signaling axis between PD-1 and its ligand PD-L1 with mAbs such as pembrolizumab (Keytruda) and nivolumab (Optivo<sup>&#174;</sup>) has shown remarkable clinical success in some cancer patients [<xref rid="B166" ref-type="bibr">166</xref>,<xref rid="B167" ref-type="bibr">167</xref>]. Such monotherapies have demonstrated impressive activity across a broad set of cancer subtypes, even at advanced and metastatic stages of disease [<xref rid="B168" ref-type="bibr">168&#8211;173</xref>]. However, 70&#8211;80% of patients receiving anti-PD-1 therapy, such as Keytruda and Optivo, remain resistant to this therapy and will not respond or will relapse, leaving a substantial unmet medical need [<xref rid="B174" ref-type="bibr">174</xref>]. PD-1/PD-L1-targeted mAbs are now the standard of care for 16 different types of cancer and tissue-agnostic indication. Since the first PD-1/PD-L1 trial landscape survey conducted in September 2017, 23 additional approvals have been granted to PD-1/PD-L1 mAbs by the FDA, and four new PD-1 mAbs have reached the market, bringing the total on the global market to nine [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>Thus, it is clear that there is significant need to develop novel immune-based therapies that have the potential to circumvent mechanisms of resistance to achieve long-term control without causing toxicities associated with combination regimens. We have shown that vaccines to HER-2 can overcome many of the obstacles associated with mAb therapies. We therefore set out to develop a vaccine for PD-1 and combine it with our HER-2 vaccine. We have created and established the development of a novel B-cell peptide vaccine (PD1-Vaxx) with high immunogenicity that binds to human PD-1 and produces tumor inhibition <italic toggle="yes">in vivo</italic> in two animal models of colon cancer. The antitumor activity and toxicity profile was investigated in mice and beagles.</p><p>We designed several PD-1 vaccine B-cell epitopes using peptide mapping, predictive antigenicity algorithms and rational design based on 3D structure of PD-1/PD-L1 and PD-1/nivolumab/pembrolizumab. The vaccine was engineered into a B-cell chimeric vaccine based on the ectodomain of PD-1 linked to a &#8216;promiscuous&#8217; T-helper cell MVF. The specificity of the selected PD-1 peptides to PD-L1 and nivolumab was demonstrated by surface plasmon resonance spectroscopy. The immunogenicity of the various individual peptide epitopes was then established in rabbits and Balb/c mice-eliciting antibodies that recognized the immunogenic sequences and the recombinant human PD-1. The transferable human colorectal CT-26 tumor model in syngeneic Balb/c mice was used to evaluate the effects of vaccination treatments with the four PD-1 MVF-peptide chimeras as inhibitors on the growth of CT-26 tumor cells. Only the 92&#8211;110 epitope (PD1-Vaxx) significantly reduced tumor growth compared with treatment with a mouse surrogate antagonist antibody anti-PD-1 mAb (29F.1A12).</p><p>Imugene presented the PD1-Vaxx Clinical Plan at the American Association for Cancer Research 2020 Annual Meeting scheduled for 27th&#8211;28th April 2020: VPO.CT01 &#8211; Phase I clinical trials from 9.00 am Eastern Daylight Time, USA, on Monday, 27th April. The abstract presentation is entitled &#8216;IMU-201-101 an open-label, multicenter, dose escalation/expansion, Phase I study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with NSCLC,&#8217; and was authored by Professor P Kaumaya at the Ohio State University, Ohio, USA; Professor T Bekaii-Saab at the Mayo Clinic, Arizona, USA; Dr T Phan, at St Vincent&#8217;s Clinical School, UNSW, AUS, Dr M Marino, Dr N Ede &amp; Dr A Good from Imugene Ltd.</p><p>The first-in-human, Phase I, multicenter, dose escalation study of PD1-Vaxx, is targeting patients with NSCLC and will be testing different doses of PD1-Vaxx as monotherapy and in combination with immune checkpoint inhibitors. The primary objective of the Phase I trial is to determine safety and an optimal biological dose as monotherapy and in combination with immune checkpoint inhibitors. Efficacy, tolerability and immune response will also be measured.</p><sec id="S0032"><title>Combination IO vaccine strategies</title><p>Combinations of checkpoint-blocking antibodies are more efficacious than single inhibitors, but also cause greater immune-related toxicities [<xref rid="B174" ref-type="bibr">174</xref>]. A large body of data are evolving on the combinations of immune checkpoint inhibitors [<xref rid="B175" ref-type="bibr">175</xref>] with chemotherapy, radiotherapy or targeted therapies [<xref rid="B176" ref-type="bibr">176</xref>]. The emerging hypothesis is to move from pragmatic therapeutic combinations to one of rational design, based on the compatibility of mechanisms that can act synergistically. We then set out to combine the PD1-Vaxx with our B-Vaxx (combo HER-2) to examine whether we can obtain higher efficacy in syngeneic Balb/c model. In another colon carcinoma Balb/c model challenged with CT26/HER-2 cell line, PD1-Vaxx outperformed the industry-standard mouse anti-PD-1 antibody in a mouse model of HER-2-positive CRC. Combined triple vaccination (PD1-Vaxx and B-Vaxx) was more effective in the CT-26/HER-2 carcinoma cell line in syngeneic Balb/c that exhibited superior activity compared with the positive gold control antimouse PD-1 (CD279) mAb.</p><p>The preliminary results of the development of the PD-1 vaccine was presented at the 2019 AACR meeting (Atlanta) in Proceedings of the American Association for Cancer Research Annual Meeting 2019, March 29&#8211;April 3, Atlanta GA. Philadelphia (PA): AACR: Cancer Res 2019: 79 (13 Suppl): Abstract#1453; and also at the 2019 ESMO meeting (Barcelona) Annals Of Oncology (2019) 30 (Suppl_5): V475&#8211;V532. 10.1093/Annonc/Mdz253. As far as I know these results are the first combination of B-cell epitope peptide vaccine (HER-2) therapy with a vaccine developed for immune checkpoint inhibitor (PD-1) that acted synergistically to induce antitumor immune responses.</p></sec><sec id="S0033"><title>Future IO landscape</title><p>There is a need to develop novel vaccination strategies, using them in combination with targeted therapies or other immunotherapeutic agents, such as checkpoint inhibitors, in order to address tumor-induced immunosuppression [<xref rid="B177" ref-type="bibr">177</xref>]. The recent developments in IO have opened an unprecedented avenue for the emergence of vaccine strategies. Several other checkpoint molecules are under investigation, such as TIM-3 and LAG-3. TIM-3, as a checkpoint inhibitor, suppresses effector T-cell activation, whereas LAG-3 acts by binding to MHC molecules and also inhibits T-cell activation and proliferation [<xref rid="B178" ref-type="bibr">178</xref>,<xref rid="B179" ref-type="bibr">179</xref>]. LAG-3 is coexpressed with PD-1 on T cells, making it a suitable candidate for a combinatorial approach with anti-PD-1 agents. Antibodies against TIM-3 and LAG-3 are under clinical investigation showing encouraging efficacy. We are presently pursuing developing vaccines for TIM3 and LAG 3 that is being used in combination with PD1-Vaxx (<xref ref-type="fig" rid="F6">Figure 6</xref>). In conclusion, the IO landscape is rapidly evolving and current enthusiasm will only surge in coming years with emerging novel approaches (<xref ref-type="fig" rid="F7">Figure 7</xref>) that exhibit increased clinical efficacy, unique survival benefits and safety profiles with potential synergistic effects.</p><fig id="F7" orientation="portrait" position="float"><label>Figure 7.<x xml:space="preserve">&#160;</x></label><caption><title>Future immuno-oncology landscape: evolving approach to combination cancer therapy.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fon-16-1767-g7.jpg"/></fig><boxed-text id="BB1" position="float" orientation="portrait"><caption><title>Executive summary</title></caption><list list-type="bullet"><list-item><p>Peptide-based vaccines have been used in the past with a limited clinical success. However, during the last few years, new knowledge has been provided on the biological characteristics of the peptides and their interaction with the immune system to be used in the clinic.</p></list-item><list-item><p>The role of B-cell humoral immunity in cancer is under appreciated and underdeveloped.</p></list-item><list-item><p>Cancer vaccines based on B-cell peptides are generally composed of an adjuvant and an immunogenic protein containing a B-cell epitope peptide that can induce B cells to create polyclonal antibodies.</p></list-item><list-item><p>Developed novel approaches such as active immunization against receptor tyrosine kinases that offer an alternative and effective treatment options.</p></list-item><list-item><p>The idea of active immunotherapy with chimeric B-cell epitope peptides incorporating a &#8216;promiscuous&#8217; T-cell epitope that elicits a polyclonal antibody response provides safe, cost-effective therapeutic advantage over monoclonal antibodies.</p></list-item><list-item><p>B-Vaxx peptides were engineered to mimic conformational epitopes on the basis of those defined by the 3D structures of HER-2/pertuzumab and HER-2/trastuzumab complexes.</p></list-item><list-item><p>It is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment and host factors informing treatment combination decisions.</p></list-item><list-item><p>Current enthusiasm about cancer immunotherapy stems from the success of checkpoint inhibitor blockade with antibodies specific for CTL-4 or PD-1. However, 70&#8211;80% patients receiving anti-PD-1 therapy remain resistant to this therapy and will not respond or will relapse, leaving a substantial unmet medical need.</p></list-item><list-item><p>More than 3000 clinical trials are evaluating the clinical activity of the PD-1 checkpoint inhibitors as monotherapies and in combinations with other cancer therapies developed and implemented an effective novel PD-1 vaccine that when combined with our HER-2 vaccine acts synergistically to enhance immune mediated tumor killing in a syngeneic model.</p></list-item><list-item><p>Thus, it is clear that there is significant need to develop novel immune-based therapies that have the potential to circumvent mechanisms of resistance to achieve long-term control without causing toxicities associated with combination regimens.</p></list-item><list-item><p>There is a need to develop novel vaccination strategies, using them in combination with targeted therapies or other immunotherapeutic agents, such as checkpoint inhibitors, in order to address tumor-induced immunosuppression.</p></list-item><list-item><p>Combinations of checkpoint-blocking antibodies are more efficacious than single inhibitors, but also cause greater immune-related toxicities.</p></list-item><list-item><p>The emerging hypothesis is to move from pragmatic therapeutic combinations to one of rational design, based on the compatibility of mechanisms that can act synergistically.</p></list-item><list-item><p>Combine the PD1-Vaxx with our B-Vaxx (combo HER-2) to examine whether we can obtain higher efficacy in syngeneic Balb/c model. In another colon carcinoma Balb/c model challenged with CT-26/HER-2 cell line.</p></list-item><list-item><p>PD1-Vaxx outperformed the industry-standard mouse anti-PD-1 antibody in a mouse model of HER-2-positive colorectal cancer. Combined triple vaccination (PD1-Vaxx and B-Vaxx) was more effective in the CT-26/HER-2 carcinoma cell line in syngeneic Balb/c, which exhibited superior activity compared with the positive gold control antimouse PD-1 (CD279) monoclonal antibody.</p></list-item></list></boxed-text></sec></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Financial &amp; competing interests disclosure</bold></p><p>This study was partly funded by NIH R01CA84356, NIH R21CA13508 to PTP Kaumaya. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p><p>No writing assistance was utilized in the production of this manuscript.</p></fn><fn><p><bold>Open access</bold></p><p>This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>Yu J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hodge</surname><given-names>JP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Oliva</surname><given-names>C</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Neftelinov</surname><given-names>ST</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hubbard-Lucey</surname><given-names>VM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name></person-group><article-title>Trends in clinical development for PD-1/PD-L1 inhibitors</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>19</volume>(<issue>3</issue>), <fpage>163</fpage>&#8211;<lpage>164</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32127660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41573-019-00182-w</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>A paradigm shift: cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: emerging concepts and validation of combination immunotherapy</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>11</volume>(<issue>6</issue>), <fpage>1368</fpage>&#8211;<lpage>1386</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25874884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1026495</pub-id><pub-id pub-id-type="pmcid">PMC4514180</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name></person-group><article-title>Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy</article-title>. <source>Future Oncol.</source><volume>8</volume>(<issue>8</issue>), <fpage>961</fpage>&#8211;<lpage>987</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22894670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon.12.95</pub-id><pub-id pub-id-type="pmcid">PMC4591923</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics</article-title>. <source>Immunotherapy</source><volume>5</volume>(<issue>11</issue>), <fpage>1159</fpage>&#8211;<lpage>1163</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">24188668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt.13.128</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics</article-title>. <source>Discov. Med.</source><volume>15</volume>(<issue>82</issue>), <fpage>166</fpage>&#8211;<lpage>176</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23545045</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Largeot</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Pagano</surname><given-names>G</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gonder</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Moussay</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Paggetti</surname><given-names>J</given-names></name></person-group><article-title>The B-side of cancer immunity: the underrated tune</article-title>. <source>Cells</source><volume>8</volume>(<issue>5</issue>), <fpage>449</fpage> (<year>2019</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells8050449</pub-id><pub-id pub-id-type="pmcid">PMC6562515</pub-id><pub-id pub-id-type="pmid">31086070</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kametani</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Miyamoto</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tsuda</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tokuda</surname><given-names>Y</given-names></name></person-group><article-title>B cell epitope-based vaccination therapy</article-title>. <source>Antibodies.</source><volume>4</volume>, <lpage>225</lpage>&#8211; <fpage>239 </fpage> (<year>2015). </year></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malonis</surname><given-names>RJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lai</surname><given-names>JR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Vergnolle</surname><given-names>O</given-names></name></person-group><article-title>Peptide-based vaccines: current progress and future challenges</article-title>. <source>Chem. Rev.</source><volume>120</volume>(<issue>6</issue>), <fpage>3210</fpage>&#8211;<lpage>3229 </lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31804810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrev.9b00472</pub-id><pub-id pub-id-type="pmcid">PMC7094793</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lindstrom</surname><given-names>AR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lin</surname><given-names>TY</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lam</surname><given-names>KS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Peptide-based materials for cancer immunotherapy</article-title>. <source>Theranostics</source><volume>9</volume>(<issue>25</issue>), <fpage>7807</fpage>&#8211;<lpage>7825</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31695802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.37194</pub-id><pub-id pub-id-type="pmcid">PMC6831480</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollingsworth</surname><given-names>RE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Jansen</surname><given-names>K</given-names></name></person-group><article-title>Turning the corner on therapeutic cancer vaccines</article-title>. <source>NPJ Vaccines</source><volume>4</volume>, <fpage>7</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30774998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-019-0103-y</pub-id><pub-id pub-id-type="pmcid">PMC6368616</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantoff</surname><given-names>PW</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Higano</surname><given-names>CS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Shore</surname><given-names>ND</given-names></name></person-group><etal/><article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title>. <source>N. Engl. J. Med.</source><volume>363</volume>(<issue>5</issue>), <fpage>411</fpage>&#8211;<lpage>422</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20818862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1001294</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>KK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Li</surname><given-names>WA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Mooney</surname><given-names>DJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Dranoff</surname><given-names>G</given-names></name></person-group><article-title>Advances in therapeutic cancer vaccines</article-title>. <source>Adv. Immunol.</source><volume>130</volume>, <fpage>191</fpage>&#8211;<lpage>249</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26923002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.ai.2015.12.001</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ott</surname><given-names>PA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wu</surname><given-names>CJ</given-names></name></person-group><article-title>Towards personalized, tumour-specific, therapeutic vaccines for cancer</article-title>. <source>Nat. Rev. Immunol.</source><volume>18</volume>(<issue>3</issue>), <fpage>168</fpage>&#8211;<lpage>182</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29226910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2017.131</pub-id><pub-id pub-id-type="pmcid">PMC6508552</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirayama</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nishimura</surname><given-names>Y</given-names></name></person-group><article-title>The present status and future prospects of peptide-based cancer vaccines</article-title>. <source>Int. Immunol.</source><volume>28</volume>(<issue>7</issue>), <fpage>319</fpage>&#8211;<lpage>328</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27235694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intimm/dxw027</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nandy</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Basak</surname><given-names>SC</given-names></name></person-group><article-title>A brief review of computer-assisted approaches to rational design of peptide vaccines</article-title>. <source>Int. J. Mol. Sci.</source><volume>17</volume>(<issue>5</issue>), <fpage>pii: E666 </fpage> (<year>2016</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms17050666</pub-id><pub-id pub-id-type="pmcid">PMC4881492</pub-id><pub-id pub-id-type="pmid">27153063</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leach</surname><given-names>DR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Krummel</surname><given-names>MF</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>Enhancement of antitumor immunity by CTLA-4 blockade</article-title>. <source>Science</source><volume>271</volume>(<issue>5256</issue>), <fpage>1734</fpage>&#8211;<lpage>1736</lpage> (<year>1996</year>).<pub-id pub-id-type="pmid">8596936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.271.5256.1734</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thommen</surname><given-names>DS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Schumacher</surname><given-names>TN</given-names></name></person-group><article-title>T cell dysfunction in cancer</article-title>. <source>Cancer Cell</source><volume>33</volume>(<issue>4</issue>), <fpage>547</fpage>&#8211;<lpage>562</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29634943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2018.03.012</pub-id><pub-id pub-id-type="pmcid">PMC7116508</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saxena</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group><article-title>Re-emergence of dendritic cell vaccines for cancer treatment</article-title>. <source>Trends Cancer</source><volume>4</volume>(<issue>2</issue>), <fpage>119</fpage>&#8211;<lpage>137</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29458962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2017.12.007</pub-id><pub-id pub-id-type="pmcid">PMC5823288</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hudziak</surname><given-names>RM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lewis</surname><given-names>GD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Winget</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Fendly</surname><given-names>BM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Shepard</surname><given-names>HM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ullrich</surname><given-names>A</given-names></name></person-group><article-title>p185HER2 monoclonal antibody has antiproliferative effects <italic toggle="yes">in vitro</italic> and sensitizes human breast tumor cells to tumor necrosis factor</article-title>. <source>Mol. Cell. Biol.</source><volume>9</volume>(<issue>3</issue>), <fpage>1165</fpage>&#8211;<lpage>1172</lpage> (<year>1989</year>).<pub-id pub-id-type="pmid">2566907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mcb.9.3.1165</pub-id><pub-id pub-id-type="pmcid">PMC362707</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shepard</surname><given-names>HM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lewis</surname><given-names>GD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Sarup</surname><given-names>JC</given-names></name></person-group><etal/><article-title>Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic</article-title>. <source>J. Clin. Immunol.</source><volume>11</volume>(<issue>3</issue>), <fpage>117</fpage>&#8211;<lpage>127</lpage> (<year>1991</year>).<pub-id pub-id-type="pmid">1679763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00918679</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>AJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wedge</surname><given-names>SR</given-names></name></person-group><article-title>ZD6474&#8211;a novel inhibitor of VEGFR and EGFR tyrosine kinase activity</article-title>. <source>Br. J. Cancer</source><volume>92</volume>(<issue>Suppl. 1</issue>), <fpage>S6</fpage>&#8211;<lpage>S13</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15928657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6602603</pub-id><pub-id pub-id-type="pmcid">PMC2362058</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ogasawara</surname><given-names>AK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name></person-group><etal/><article-title>KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF</article-title>. <source>Hypertension</source><volume>39</volume>(<issue>6</issue>), <fpage>1095</fpage>&#8211;<lpage>1100</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12052848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.hyp.0000018588.56950.7a</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eskens</surname><given-names>FA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Verweij</surname><given-names>J</given-names></name></person-group><article-title>The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review</article-title>. <source>Eur. J. Cancer</source><volume>42</volume>(<issue>18</issue>), <fpage>3127</fpage>&#8211;<lpage>3139</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">17098419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2006.09.015</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grothey</surname><given-names>A</given-names></name></person-group><article-title>Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer</article-title>. <source>Oncology</source><volume>20</volume>(<issue>10 Suppl. 14</issue>), <fpage>21</fpage>&#8211;<lpage>28</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">17354514</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Presta</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gorman</surname><given-names>CM</given-names></name></person-group><etal/><article-title>Humanization of an anti-p185HER2 antibody for human cancer therapy</article-title>. <source>Proc. Natl Acad. Sci. USA</source><volume>89</volume>(<issue>10</issue>), <fpage>4285</fpage>&#8211;<lpage>4289</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1350088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.89.10.4285</pub-id><pub-id pub-id-type="pmcid">PMC49066</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agus</surname><given-names>DB</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Akita</surname><given-names>RW</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Fox</surname><given-names>WD</given-names></name></person-group><etal/><article-title>Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth</article-title>. <source>Cancer Cell</source><volume>2</volume>(<issue>2</issue>), <fpage>127</fpage>&#8211;<lpage>137</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12204533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1535-6108(02)00097-1</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agus</surname><given-names>DB</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gordon</surname><given-names>MS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Taylor</surname><given-names>C</given-names></name></person-group><etal/><article-title>Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer</article-title>. <source>J. Clin. Oncol.</source><volume>23</volume>(<issue>11</issue>), <fpage>2534</fpage>&#8211;<lpage>43</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15699478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.03.184</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nahta</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hung</surname><given-names>MC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Esteva</surname><given-names>FJ</given-names></name></person-group><article-title>The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells</article-title>. <source>Cancer Res.</source><volume>64</volume>(<issue>7</issue>), <fpage>2343</fpage>&#8211;<lpage>2346</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15059883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.can-03-3856</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>Phillips GD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Dugger</surname><given-names>DL</given-names></name></person-group><etal/><article-title>Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</article-title>. <source>Cancer Res.</source><volume>68</volume>(<issue>22</issue>), <fpage>9280</fpage>&#8211;<lpage>9290</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">19010901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-08-1776</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modi</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Saura</surname><given-names>C</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name></person-group><etal/><article-title>Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</article-title>. <source>N. Engl. J. Med.</source><volume>382</volume>(<issue>7</issue>), <fpage>610</fpage>&#8211;<lpage>621</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">31825192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1914510</pub-id><pub-id pub-id-type="pmcid">PMC7458671</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boohaker</surname><given-names>RJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lee</surname><given-names>MW</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Vishnubhotla</surname><given-names>P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Perez</surname><given-names>JM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Khaled</surname><given-names>AR</given-names></name></person-group><article-title>The use of therapeutic peptides to target and to kill cancer cells</article-title>. <source>Curr. Med. Chem.</source><volume>19</volume>(<issue>22</issue>), <fpage>3794</fpage>&#8211;<lpage>3804</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22725698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/092986712801661004</pub-id><pub-id pub-id-type="pmcid">PMC4537071</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahrens</surname><given-names>VM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Bellmann-Sickert</surname><given-names>K</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Beck-Sickinger</surname><given-names>AG</given-names></name></person-group><article-title>Peptides and peptide conjugates: therapeutics on the upward path</article-title>. <source>Future Med. Chem.</source><volume>4</volume>(<issue>12</issue>), <fpage>1567</fpage>&#8211;<lpage>1586</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22917246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/fmc.12.76</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>EM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Otero</surname><given-names>DA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Banks</surname><given-names>WA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>O&#8217;Brien</surname><given-names>JS</given-names></name></person-group><article-title>Retro-inverso prosaptide peptides retain bioactivity, are stable <italic toggle="yes">in vivo</italic>, and are blood&#8211;brain barrier permeable</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>295</volume>(<issue>1</issue>), <fpage>190</fpage>&#8211;<lpage>194</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10991978</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wardrop</surname><given-names>RM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gienapp</surname><given-names>IE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Stuckman</surname><given-names>SS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Whitacre</surname><given-names>CC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells <italic toggle="yes">in vitro</italic></article-title>. <source>J. Immunol.</source><volume>167</volume>(<issue>1</issue>), <fpage>578</fpage>&#8211;<lpage>585</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11418697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.167.1.578</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gienapp</surname><given-names>IE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Stuckman</surname><given-names>SS</given-names></name></person-group><etal/><article-title>Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28</article-title>. <source>J. Immunol.</source><volume>169</volume>(<issue>4</issue>), <fpage>2180</fpage>&#8211;<lpage>2188</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12165548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.169.4.2180</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>SD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rawale</surname><given-names>SV</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Whitacre</surname><given-names>CC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade</article-title>. <source>J. Pept. Res.</source><volume>65</volume>(<issue>6</issue>), <fpage>591</fpage>&#8211;<lpage>604</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15885118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-3011.2005.00256.x</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>PM</given-names></name></person-group><article-title>The design, synthesis and application of stereochemical and directional peptide isomers: a critical review</article-title>. <source>Curr. Protein Pept. Sci.</source><volume>4</volume>(<issue>5</issue>), <fpage>339</fpage>&#8211;<lpage>356</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">14529528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389203033487054</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>MD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Campbell</surname><given-names>MM</given-names></name></person-group><article-title>Partially modified retro-inverso peptides: development, synthesis, and conformational behavior</article-title>. <source>Chem. Rev.</source><volume>98</volume>(<issue>2</issue>), <fpage>763</fpage>&#8211;<lpage>796</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">11848914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/cr970468t</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slingluff</surname><given-names>CL</given-names><suffix>Jr</suffix></name></person-group><article-title>The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?</article-title><source>Cancer J.</source><volume>17</volume>(<issue>5</issue>), <fpage>343</fpage>&#8211;<lpage>350</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21952285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PPO.0b013e318233e5b2</pub-id><pub-id pub-id-type="pmcid">PMC3204371</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>The future of immune checkpoint therapy</article-title>. <source>Science</source><volume>348</volume>(<issue>6230</issue>), <fpage>56</fpage>&#8211;<lpage>61</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25838373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaa8172</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinmann</surname><given-names>H</given-names></name></person-group><article-title>Cancer immunotherapy: selected targets and small-molecule modulators</article-title>. <source>ChemMedChem</source><volume>11</volume>(<issue>5</issue>), <fpage>450</fpage>&#8211;<lpage>466</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26836578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.201500566</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finn</surname><given-names>OJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rammensee</surname><given-names>HG</given-names></name></person-group><article-title>Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Neoantigens: nothing new in spite of the name</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source><volume>10</volume>(<issue>11</issue>), <fpage>a028829 </fpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29254980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a028829</pub-id><pub-id pub-id-type="pmcid">PMC6211383</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>TN</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kishton</surname><given-names>RJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Restifo</surname><given-names>NP</given-names></name></person-group><article-title>Developing neoantigen-targeted T cell-based treatments for solid tumors</article-title>. <source>Nat. Med.</source><volume>25</volume>(<issue>10</issue>), <fpage>1488</fpage>&#8211;<lpage>1499</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31591590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-019-0596-y</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchbinder</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hodi</surname><given-names>FS</given-names></name></person-group><article-title>Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade</article-title>. <source>J. Clin. Invest.</source><volume>125</volume>(<issue>9</issue>), <fpage>3377</fpage>&#8211;<lpage>3383</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26325034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI80012</pub-id><pub-id pub-id-type="pmcid">PMC4588295</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topalian</surname><given-names>SL</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Drake</surname><given-names>CG</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>Immune checkpoint blockade: a common denominator approach to cancer therapy</article-title>. <source>Cancer Cell</source><volume>27</volume>(<issue>4</issue>), <fpage>450</fpage>&#8211;<lpage>461</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25858804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2015.03.001</pub-id><pub-id pub-id-type="pmcid">PMC4400238</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Z</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Qian</surname><given-names>Q</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Qian</surname><given-names>Q</given-names></name></person-group><article-title>Cancer vaccine: learning lessons from immune checkpoint inhibitors</article-title>. <source>J. Cancer</source><volume>9</volume>(<issue>2</issue>), <fpage>263</fpage>&#8211;<lpage>268</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29344272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/jca.20059</pub-id><pub-id pub-id-type="pmcid">PMC5771333</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cebon</surname><given-names>J</given-names></name></person-group><article-title>Perspective: cancer vaccines in the era of immune checkpoint blockade</article-title>. <source>Mamm. Genome</source><volume>29</volume>(<issue>11&#8211;12</issue>), <fpage>703</fpage>&#8211;<lpage>713</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30446791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00335-018-9786-z</pub-id><pub-id pub-id-type="pmcid">PMC6267701</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzahar</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Waterman</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><etal/><article-title>A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor</article-title>. <source>Mol. Cell. Biol.</source><volume>16</volume>(<issue>10</issue>), <fpage>5276</fpage>&#8211;<lpage>5287</lpage> (<year>1996</year>).<pub-id pub-id-type="pmid">8816440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mcb.16.10.5276</pub-id><pub-id pub-id-type="pmcid">PMC231527</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graus-Porta</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Beerli</surname><given-names>RR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Daly</surname><given-names>JM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hynes</surname><given-names>NE</given-names></name></person-group><article-title>ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling</article-title>. <source>EMBO J.</source><volume>16</volume>(<issue>7</issue>), <fpage>1647</fpage>&#8211;<lpage>1655</lpage> (<year>1997</year>).<pub-id pub-id-type="pmid">9130710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/emboj/16.7.1647</pub-id><pub-id pub-id-type="pmcid">PMC1169769</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beerli</surname><given-names>RR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Graus-Porta</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Woods-Cook</surname><given-names>K</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Yarden</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hynes</surname><given-names>NE</given-names></name></person-group><article-title>Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2</article-title>. <source>Mol. Cell. Biol.</source><volume>15</volume>(<issue>12</issue>), <fpage>6496</fpage>&#8211;<lpage>6505</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">8524214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mcb.15.12.6496</pub-id><pub-id pub-id-type="pmcid">PMC230902</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graus-Porta</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Beerli</surname><given-names>RR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hynes</surname><given-names>NE</given-names></name></person-group><article-title>Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling</article-title>. <source>Mol. Cell. Biol.</source><volume>15</volume>(<issue>3</issue>), <fpage>1182</fpage>&#8211;<lpage>1191</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7532277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mcb.15.3.1182</pub-id><pub-id pub-id-type="pmcid">PMC230341</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>DJ</given-names></name></person-group><article-title>Studies of the HER-2/neu proto-oncogene in human breast cancer</article-title>. <source>Cancer Invest.</source><volume>8</volume>(<issue>2</issue>), <fpage>253</fpage> (<year>1990</year>).<pub-id pub-id-type="pmid">1976032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/07357909009017573</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirisano</surname><given-names>FD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Karlan</surname><given-names>BY</given-names></name></person-group><article-title>The role of the HER-2/neu oncogene in gynecologic cancers</article-title>. <source>J. Soc. Gynecol. Investig.</source><volume>3</volume>(<issue>3</issue>), <fpage>99</fpage>&#8211;<lpage>105</lpage> (<year>1996</year>).<pub-id pub-id-type="pmid">8796816</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berchuck</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rodriguez</surname><given-names>G</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kinney</surname><given-names>RB</given-names></name></person-group><etal/><article-title>Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease</article-title>. <source>Am. J. Obstet. Gynecol.</source><volume>164</volume>(<issue>1 Pt 1</issue>), <fpage>15</fpage>&#8211;<lpage>21</lpage> (<year>1991</year>).<pub-id pub-id-type="pmid">1670908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9378(91)90615-x</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kern</surname><given-names>JA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Schwartz</surname><given-names>DA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nordberg</surname><given-names>JE</given-names></name></person-group><etal/><article-title>p185neu expression in human lung adenocarcinomas predicts shortened survival</article-title>. <source>Cancer Res.</source><volume>50</volume>(<issue>16</issue>), <fpage>5184</fpage>&#8211;<lpage>5187</lpage> (<year>1990</year>).<pub-id pub-id-type="pmid">1974168</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>RL</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hawkins</surname><given-names>NJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Coomber</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Disis</surname><given-names>ML</given-names></name></person-group><article-title>Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer</article-title>. <source>Hum. Immunol.</source><volume>60</volume>(<issue>6</issue>), <fpage>510</fpage>&#8211;<lpage>515</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10408800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0198-8859(99)00003-8</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>DJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Clark</surname><given-names>GM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wong</surname><given-names>SG</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Levin</surname><given-names>WJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ullrich</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>McGuire</surname><given-names>WL</given-names></name></person-group><article-title>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title>. <source>Science</source><volume>235</volume>(<issue>4785</issue>), <fpage>177</fpage>&#8211;<lpage>182</lpage> (<year>1987</year>).<pub-id pub-id-type="pmid">3798106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.3798106</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baselga</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Arteaga</surname><given-names>CL</given-names></name></person-group><article-title>Critical update and emerging trends in epidermal growth factor receptor targeting in cancer</article-title>. <source>J. Clin. Oncol.</source><volume>23</volume>(<issue>11</issue>), <fpage>2445</fpage>&#8211;<lpage>2459</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15753456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.11.890</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baselga</surname><given-names>J</given-names></name></person-group><article-title>Targeting tyrosine kinases in cancer: the second wave</article-title>. <source>Science</source><volume>312</volume>(<issue>5777</issue>), <fpage>1175</fpage>&#8211;<lpage>1178</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16728632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1125951</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>RK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Duda</surname><given-names>DG</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Clark</surname><given-names>JW</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Loeffler</surname><given-names>JS</given-names></name></person-group><article-title>Lessons from Phase III clinical trials on anti-VEGF therapy for cancer</article-title>. <source>Nat. Clin. Pract. Oncol.</source><volume>3</volume>(<issue>1</issue>), <fpage>24</fpage>&#8211;<lpage>40</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16407877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncponc0403</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houck</surname><given-names>KA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ferrara</surname><given-names>N</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Winer</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Cachianes</surname><given-names>G</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Leung</surname><given-names>DW</given-names></name></person-group><article-title>The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA</article-title>. <source>Mol. Endocrinol.</source><volume>5</volume>(<issue>12</issue>), <fpage>1806</fpage>&#8211;<lpage>1814</lpage> (<year>1991</year>).<pub-id pub-id-type="pmid">1791831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/mend-5-12-1806</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cobleigh</surname><given-names>MA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Langmuir</surname><given-names>VK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Sledge</surname><given-names>GW</given-names></name></person-group><etal/><article-title>A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer</article-title>. <source>Semin. Oncol.</source><volume>30</volume>(<issue>16 Suppl. 5</issue>), <fpage>117</fpage>&#8211;<lpage>124</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">14613032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.seminoncol.2003.08.013</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hynes</surname><given-names>NE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lane</surname><given-names>HA</given-names></name></person-group><article-title>ERBB receptors and cancer: the complexity of targeted inhibitors</article-title>. <source>Nat. Rev. Cancer</source><volume>5</volume>(<issue>5</issue>), <fpage>341</fpage>&#8211;<lpage>354</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15864276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1609</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoeben</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Landuyt</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Highley</surname><given-names>MS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wildiers</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Van Oosterom</surname><given-names>AT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>De</surname><given-names>Bruijn EA</given-names></name></person-group><article-title>Vascular endothelial growth factor and angiogenesis</article-title>. <source>Pharmacol. Rev.</source><volume>56</volume>(<issue>4</issue>), <fpage>549</fpage>&#8211;<lpage>580</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15602010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pr.56.4.3</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Witte</surname><given-names>L</given-names></name></person-group><article-title>Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor</article-title>. <source>Invest. New Drugs</source><volume>17</volume>(<issue>3</issue>), <fpage>195</fpage>&#8211;<lpage>212</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10665474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1006314501634</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshima</surname><given-names>RG</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lesperance</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Munoz</surname><given-names>V</given-names></name></person-group><etal/><article-title>Angiogenic acceleration of Neu induced mammary tumor progression and metastasis</article-title>. <source>Cancer Res.</source><volume>64</volume>(<issue>1</issue>), <fpage>169</fpage>&#8211;<lpage>179</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">14729621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.can-03-1944</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folkman</surname><given-names>J</given-names></name></person-group><article-title>Tumor angiogenesis: therapeutic implications</article-title>. <source>N. Engl. J. Med.</source><volume>285</volume>(<issue>21</issue>), <fpage>1182</fpage>&#8211;<lpage>1186</lpage> (<year>1971</year>).<pub-id pub-id-type="pmid">4938153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM197111182852108</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hynes</surname><given-names>NE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Stern</surname><given-names>DF</given-names></name></person-group><article-title>The biology of erbB-2/neu/HER-2 and its role in cancer</article-title>. <source>Biochim. Biophys. Acta</source><volume>1198</volume>(<issue>2&#8211;3</issue>), <fpage>165</fpage>&#8211;<lpage>184</lpage> (<year>1994</year>).<pub-id pub-id-type="pmid">7819273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0304-419x(94)90012-4</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholl</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Beuzeboc</surname><given-names>P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Pouillart</surname><given-names>P</given-names></name></person-group><article-title>Targeting HER2 in other tumor types</article-title>. <source>Ann. Oncol.</source><volume>12</volume>(<issue>Suppl. 1</issue>), <fpage>S81</fpage>&#8211;<lpage>S87</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11521727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/12.suppl_1.s81</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>DJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Godolphin</surname><given-names>W</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Jones</surname><given-names>LA</given-names></name></person-group><etal/><article-title>Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</article-title>. <source>Science</source><volume>244</volume>(<issue>4905</issue>), <fpage>707</fpage>&#8211;<lpage>712</lpage> (<year>1989</year>).<pub-id pub-id-type="pmid">2470152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.2470152</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dakappagari</surname><given-names>NK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Douglas</surname><given-names>DB</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Triozzi</surname><given-names>PL</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Stevens</surname><given-names>VC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine</article-title>. <source>Cancer Res.</source><volume>60</volume>(<issue>14</issue>), <fpage>3782</fpage>&#8211;<lpage>3789</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10919651</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dakappagari</surname><given-names>NK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Pyles</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Parihar</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Carson</surname><given-names>WE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Young</surname><given-names>DC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses</article-title>. <source>J. Immunol.</source><volume>170</volume>(<issue>8</issue>), <fpage>4242</fpage>&#8211;<lpage>4253</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12682258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.170.8.4242</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dakappagari</surname><given-names>NK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Sundaram</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rawale</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Liner</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Galloway</surname><given-names>DR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice</article-title>. <source>J. Pept. Res.</source><volume>65</volume>(<issue>2</issue>), <fpage>189</fpage>&#8211;<lpage>199</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15705163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-3011.2005.00212.x</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dakappagari</surname><given-names>NK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lute</surname><given-names>KD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rawale</surname><given-names>S</given-names></name></person-group><etal/><article-title>Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities</article-title>. <source>J. Biol. Chem.</source><volume>280</volume>(<issue>1</issue>), <fpage>54</fpage>&#8211;<lpage>63</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15507452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M411020200</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrett</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rawale</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Allen</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Philips</surname><given-names>G</given-names></name><x xml:space="preserve">,</x><name name-style="western"><surname>Forni</surname><given-names>G</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Morris</surname><given-names>J</given-names></name></person-group><article-title>Novel engineered ttrastuzumab conformational epitopes demonstrate <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> antitumor properties against HER-2neu</article-title>. <source>J. Immunol.</source><volume>178</volume>(<issue>11</issue>), <fpage>7120</fpage>&#8211;<lpage>7130</lpage> (<year>1992</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.178.11.7120</pub-id><pub-id pub-id-type="pmid">17513761</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Berndt</surname><given-names>KD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Heidorn</surname><given-names>DB</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Trewhella</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kezdy</surname><given-names>FJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Goldberg</surname><given-names>E</given-names></name></person-group><article-title>Synthesis and biophysical characterization of engineered topographic immunogenic determinants with alpha alpha topology</article-title>. <source>Biochemistry</source><volume>29</volume>(<issue>1</issue>), <fpage>13</fpage>&#8211;<lpage>23</lpage> (<year>1990</year>).<pub-id pub-id-type="pmid">1691014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi00453a002</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobs-Conrad</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>DiGeorge</surname><given-names>AM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PTP</given-names></name></person-group><article-title>Engineered topographic determinants with &#945;&#946;, &#946;&#945;&#946;, and &#946;&#945;&#946;&#945; topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4)</article-title>. <source>J. Biol. Chem.</source><volume>268</volume>(<issue>34</issue>), <fpage>25285</fpage>&#8211;<lpage>25295</lpage> (<year>1993</year>).<pub-id pub-id-type="pmid">8244959</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lairmore</surname><given-names>MD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>DiGeorge</surname><given-names>AM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Conrad</surname><given-names>SF</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Trevino</surname><given-names>AV</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lal</surname><given-names>RB</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction</article-title>. <source>J. Virol.</source><volume>69</volume>(<issue>10</issue>), <fpage>6077</fpage>&#8211;<lpage>6089</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7545241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.69.10.6077-6089.1995</pub-id><pub-id pub-id-type="pmcid">PMC189504</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaumaya</surname><given-names>PTP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kobs-Conrad</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Seo</surname><given-names>Young H</given-names></name></person-group><etal/><article-title>Peptide vaccines incorporating a &#8216;promiscuous&#8217; T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity</article-title>. <source>J. Mol. Recognit.</source><volume>6</volume>(<issue>2</issue>), <fpage>81</fpage>&#8211;<lpage>94</lpage> (<year>1993</year>).<pub-id pub-id-type="pmid">7508238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmr.300060206</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frangione-Beebe</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Albrecht</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Dakappagari</surname><given-names>N</given-names></name></person-group><etal/><article-title>Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide</article-title>. <source>Vaccine</source><volume>19</volume>(<issue>9&#8211;10</issue>), <fpage>1068</fpage>&#8211;<lpage>1081</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">11137241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(00)00340-6</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kaumaya</surname><given-names>PTP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kobs-Conrad</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>DiGeorge</surname><given-names>AM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Stevens</surname><given-names>V</given-names></name></person-group><article-title>Denovo engineering of protein immunogenic &amp; antigenic determinants</article-title>. : <source>Peptides.</source><person-group person-group-type="editor"><name name-style="western"><surname>Anantharamaiah</surname><given-names>GMB C</given-names></name></person-group> (). <publisher-name>Springer-Verlag</publisher-name>, <publisher-loc>Heidelberg, Germany</publisher-loc>, <fpage>133</fpage>&#8211;<lpage>164</lpage> (<year>1994</year>).</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karplus</surname><given-names>PA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Schulz</surname><given-names>GE</given-names></name></person-group><article-title>Refined structure of glutathione reductase at 1.54 A resolution</article-title>. <source>J. Mol. Biol.</source><volume>195</volume>(<issue>3</issue>), <fpage>701</fpage>&#8211;<lpage>729</lpage> (<year>1987</year>).<pub-id pub-id-type="pmid">3656429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-2836(87)90191-4</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyte</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Doolittle</surname><given-names>RF</given-names></name></person-group><article-title>A simple method for displaying the hydropathic character of a protein</article-title>. <source>J. Mol. Biol.</source><volume>157</volume>(<issue>1</issue>), <fpage>105</fpage>&#8211;<lpage>132</lpage> (<year>1982</year>).<pub-id pub-id-type="pmid">7108955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-2836(82)90515-0</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopp</surname><given-names>TP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Woods</surname><given-names>KR</given-names></name></person-group><article-title>Prediction of protein antigenic determinants from amino acid sequences</article-title>. <source>Proc. Natl Acad. Sci. USA</source><volume>78</volume>(<issue>6</issue>), <fpage>3824</fpage>&#8211;<lpage>3828</lpage> (<year>1981</year>).<pub-id pub-id-type="pmid">6167991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.78.6.3824</pub-id><pub-id pub-id-type="pmcid">PMC319665</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>GD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Geselowitz</surname><given-names>AR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lesser</surname><given-names>GJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lee</surname><given-names>RH</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zehfus</surname><given-names>MH</given-names></name></person-group><article-title>Hydrophobicity of amino acid residues in globular proteins</article-title>. <source>Science</source><volume>229</volume>(<issue>4716</issue>), <fpage>834</fpage>&#8211;<lpage>838</lpage> (<year>1985</year>).<pub-id pub-id-type="pmid">4023714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.4023714</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornton</surname><given-names>JM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Edwards</surname><given-names>MS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Taylor</surname><given-names>WR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Barlow</surname><given-names>DJ</given-names></name></person-group><article-title>Location of &#8216;continuous&#8217; antigenic determinants in the protruding regions of proteins</article-title>. <source>EMBO J.</source><volume>5</volume>(<issue>2</issue>), <fpage>409</fpage>&#8211;<lpage>413</lpage> (<year>1986</year>).<pub-id pub-id-type="pmid">2423325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1460-2075.1986.tb04226.x</pub-id><pub-id pub-id-type="pmcid">PMC1166746</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welling</surname><given-names>GW</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Weijer</surname><given-names>WJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>van</surname><given-names>der Zee R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Welling-Wester</surname><given-names>S</given-names></name></person-group><article-title>Prediction of sequential antigenic regions in proteins</article-title>. <source>FEBS Lett.</source><volume>188</volume>(<issue>2</issue>), <fpage>215</fpage>&#8211;<lpage>218</lpage> (<year>1985</year>).<pub-id pub-id-type="pmid">2411595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0014-5793(85)80374-4</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>PY</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Fasman</surname><given-names>GD</given-names></name></person-group><article-title>Prediction of the secondary structure of proteins from their amino acid sequence</article-title>. <source>Adv. Enzymol. Relat. Areas Mol. Biol.</source><volume>47</volume>, <fpage>45</fpage>&#8211;<lpage>148</lpage> (<year>1978</year>).<pub-id pub-id-type="pmid">364941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/9780470122921.ch2</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novotny</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Handschumacher</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Haber</surname><given-names>E</given-names></name></person-group><etal/><article-title>Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains)</article-title>. <source>Proc. Natl Acad. Sci. USA</source><volume>83</volume>(<issue>2</issue>), <fpage>226</fpage>&#8211;<lpage>230</lpage> (<year>1986</year>).<pub-id pub-id-type="pmid">2417241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.83.2.226</pub-id><pub-id pub-id-type="pmcid">PMC322830</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soria-Guerra</surname><given-names>RE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nieto-Gomez</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Govea-Alonso</surname><given-names>DO</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rosales-Mendoza</surname><given-names>S</given-names></name></person-group><article-title>An overview of bioinformatics tools for epitope prediction: implications on vaccine development</article-title>. <source>J. Biomed. Inform.</source><volume>53</volume>, <fpage>405</fpage>&#8211;<lpage>414</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25464113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbi.2014.11.003</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarek</surname><given-names>MM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Shafei</surname><given-names>AE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ali</surname><given-names>MA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Mansour</surname><given-names>MM</given-names></name></person-group><article-title>Computational prediction of vaccine potential epitopes and 3-dimensional structure of XAGE-1b for non-small cell lung cancer immunotherapy</article-title>. <source>Biomed. J.</source><volume>41</volume>(<issue>2</issue>), <fpage>118</fpage>&#8211;<lpage>128</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29866600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bj.2018.04.002</pub-id><pub-id pub-id-type="pmcid">PMC6138771</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivalingam</surname><given-names>GN</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Shepherd</surname><given-names>AJ</given-names></name></person-group><article-title>An analysis of B-cell epitope discontinuity</article-title>. <source>Mol. Immunol.</source><volume>51</volume>(<issue>3&#8211;4</issue>), <fpage>304</fpage>&#8211;<lpage>309</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22520973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2012.03.030</pub-id><pub-id pub-id-type="pmcid">PMC3657695</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozlova</surname><given-names>EEG</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Cerf</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Schneider</surname><given-names>FS</given-names></name></person-group><etal/><article-title>Computational B-cell epitope identification and production of neutralizing murine antibodies against Atroxlysin-I</article-title>. <source>Sci. Rep.</source><volume>8</volume>(<issue>1</issue>), <fpage>14904</fpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30297733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-33298-x</pub-id><pub-id pub-id-type="pmcid">PMC6175905</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kringelum</surname><given-names>JV</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nielsen</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Padkjaer</surname><given-names>SB</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lund</surname><given-names>O</given-names></name></person-group><article-title>Structural analysis of B-cell epitopes in antibody:protein complexes</article-title>. <source>Mol. Immunol.</source><volume>53</volume>(<issue>1&#8211;2</issue>), <fpage>24</fpage>&#8211;<lpage>34</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">22784991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2012.06.001</pub-id><pub-id pub-id-type="pmcid">PMC3461403</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jasinska</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wagner</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Radauer</surname><given-names>C</given-names></name></person-group><etal/><article-title>Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu</article-title>. <source>Int. J. Cancer</source><volume>107</volume>(<issue>6</issue>), <fpage>976</fpage>&#8211;<lpage>983</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">14601058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.11485</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiedermann</surname><given-names>U</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wiltschke</surname><given-names>C</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Jasinska</surname><given-names>J</given-names></name></person-group><etal/><article-title>A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a Phase I study</article-title>. <source>Breast Cancer Res. Treat.</source><volume>119</volume>(<issue>3</issue>), <fpage>673</fpage>&#8211;<lpage>683</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20092022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-009-0666-9</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tobias</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Jasinska</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Baier</surname><given-names>K</given-names></name></person-group><etal/><article-title>Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide</article-title>. <source>BMC Cancer</source><volume>17</volume>(<issue>1</issue>), <fpage>118</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28183282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-017-3098-7</pub-id><pub-id pub-id-type="pmcid">PMC5301331</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahdavi</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Keyhanfar</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Jafarian</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Mohabatkar</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rabbani</surname><given-names>M</given-names></name></person-group><article-title>Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer</article-title>. <source>Tumour Biol.</source><volume>35</volume>(<issue>12</issue>), <fpage>12049</fpage>&#8211;<lpage>12057</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25142233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13277-014-2503-y</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wentink</surname><given-names>MQ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hackeng</surname><given-names>TM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tabruyn</surname><given-names>SP</given-names></name></person-group><etal/><article-title>Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity</article-title>. <source>Proc. Natl Acad. Sci. USA</source><volume>113</volume>(<issue>44</issue>), <fpage>12532</fpage>&#8211;<lpage>12537</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27791128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1610258113</pub-id><pub-id pub-id-type="pmcid">PMC5098619</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vicari</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Liotta</surname><given-names>EM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PTP</given-names></name></person-group><article-title>Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways</article-title>. <source>J. Biol. Chem.</source><volume>286</volume>(<issue>15</issue>), <fpage>13612</fpage>&#8211;<lpage>13625</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21321115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M110.216812</pub-id><pub-id pub-id-type="pmcid">PMC3075706</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Phillips</surname><given-names>G</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Miller</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title>. <source>J. Biol. Chem.</source><volume>286</volume>(<issue>15</issue>), <fpage>13626</fpage>&#8211;<lpage>13637</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21325276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M110.216820</pub-id><pub-id pub-id-type="pmcid">PMC3075707</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Cohn</surname><given-names>DE</given-names></name></person-group><article-title>Immunization with synthetic VEGF peptides in ovarian cancer</article-title>. <source>Gynecol. Oncol.</source><volume>119</volume>(<issue>3</issue>), <fpage>564</fpage>&#8211;<lpage>570</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20822802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2010.07.037</pub-id><pub-id pub-id-type="pmcid">PMC4289616</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Moldovan</surname><given-names>N</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Carson</surname><given-names>WE</given-names><suffix>3rd</suffix></name>&gt;<x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title>. <source>Oncoimmunology</source><volume>1</volume>(<issue>7</issue>), <fpage>1048</fpage>&#8211;<lpage>1060</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">23170253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/onci.20708</pub-id><pub-id pub-id-type="pmcid">PMC3494619</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Cui</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Qu</surname><given-names>H</given-names></name></person-group><etal/><article-title>Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab</article-title>. <source>Oncotarget</source><volume>7</volume>(<issue>46</issue>), <fpage>75293</fpage>&#8211;<lpage>75306</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27659529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.12167</pub-id><pub-id pub-id-type="pmcid">PMC5342741</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR)</article-title>. <source>Immunol. Lett.</source><volume>153</volume>(<issue>1&#8211;2</issue>), <fpage>33</fpage>&#8211;<lpage>40</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23871733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imlet.2013.07.003</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Neninger</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>de</surname><given-names>la Torre A</given-names></name></person-group><etal/><article-title>Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine</article-title>. <source>Clin. Cancer Res.</source><volume>14</volume>(<issue>3</issue>), <fpage>840</fpage>&#8211;<lpage>846</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18245547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-07-1050</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saavedra</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Neninger</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rodriguez</surname><given-names>C</given-names></name></person-group><etal/><article-title>CIMAvax-EGF: toward long-term survival of advanced NSCLC</article-title>. <source>Semin. Oncol.</source><volume>45</volume>(<issue>1&#8211;2</issue>), <fpage>34</fpage>&#8211;<lpage>40</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30318082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.seminoncol.2018.04.009</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Garrett</surname><given-names>J</given-names></name></person-group><etal/><article-title>Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors</article-title>. <source>J. Clin. Oncol.</source><volume>27</volume>(<issue>31</issue>), <fpage>5270</fpage>&#8211;<lpage>5277</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19752336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.22.3883</pub-id><pub-id pub-id-type="pmcid">PMC2773479</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>HS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Mason</surname><given-names>K</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ramyar</surname><given-names>KX</given-names></name></person-group><etal/><article-title>Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab</article-title>. <source>Nature</source><volume>421</volume>(<issue>6924</issue>), <fpage>756</fpage>&#8211;<lpage>760</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12610629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature01392</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrett</surname><given-names>TP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>McKern</surname><given-names>NM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lou</surname><given-names>M</given-names></name></person-group><etal/><article-title>The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors</article-title>. <source>Mol. Cell</source><volume>11</volume>(<issue>2</issue>), <fpage>495</fpage>&#8211;<lpage>505</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12620236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1097-2765(03)00048-0</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franklin</surname><given-names>MC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Carey</surname><given-names>KD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Vajdos</surname><given-names>FF</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Leahy</surname><given-names>DJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>de Vos</surname><given-names>AM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Sliwkowski</surname><given-names>MX</given-names></name></person-group><article-title>Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex</article-title>. <source>Cancer Cell</source><volume>5</volume>(<issue>4</issue>), <fpage>317</fpage>&#8211;<lpage>328</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15093539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1535-6108(04)00083-2</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>SD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Garrett</surname><given-names>JT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rawale</surname><given-names>SV</given-names></name></person-group><etal/><article-title>Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth <italic toggle="yes">in vivo</italic></article-title>. <source>J. Immunol.</source><volume>179</volume>(<issue>1</issue>), <fpage>472</fpage>&#8211;<lpage>482</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17579068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.179.1.472</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaumaya</surname><given-names>P. T. P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wesolowski</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ramaswamy</surname><given-names>B</given-names></name></person-group><etal/><article-title>Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors</article-title>. <source>Clin. Cancer Res.</source><volume>25</volume>(<issue>12</issue>), <fpage>3495</fpage>&#8211;<lpage>3507</lpage> (<year>2019).</year><pub-id pub-id-type="pmid">30804020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-18-3997</pub-id><pub-id pub-id-type="pmcid">PMC7159438</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peake</surname><given-names>BF</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nahta</surname><given-names>R</given-names></name></person-group><article-title>Resistance to HER2-targeted therapies: a potential role for FOXM1</article-title>. <source>Breast Cancer Manag.</source><volume>3</volume>(<issue>5</issue>), <fpage>423</fpage>&#8211;<lpage>431</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25598845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/bmt.14.33</pub-id><pub-id pub-id-type="pmcid">PMC4294221</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nahta</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hung</surname><given-names>MC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hortobagyi</surname><given-names>GN</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Esteva</surname><given-names>FJ</given-names></name></person-group><article-title>Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer</article-title>. <source>Nat. Clin. Pract. Oncol.</source><volume>3</volume>(<issue>5</issue>), <fpage>269</fpage>&#8211;<lpage>280</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16683005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncponc0509</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dua</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nhonthachit</surname><given-names>P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Penuel</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Petropoulos</surname><given-names>C</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Parry</surname><given-names>G</given-names></name></person-group><article-title>EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance</article-title>. <source>Breast Cancer Res. Treat.</source><volume>122</volume>(<issue>3</issue>), <fpage>685</fpage>&#8211;<lpage>697</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">19859802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-009-0592-x</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group><etal/><article-title>Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin</article-title>. <source>Cancer Res.</source><volume>70</volume>(<issue>3</issue>), <fpage>1204</fpage>&#8211;<lpage>1214</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20103628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-09-3321</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junttila</surname><given-names>TT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Akita</surname><given-names>RW</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Parsons</surname><given-names>K</given-names></name></person-group><etal/><article-title>Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941</article-title>. <source>Cancer Cell</source><volume>15</volume>(<issue>5</issue>), <fpage>429</fpage>&#8211;<lpage>440</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19411071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccr.2009.03.020</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zi</surname><given-names>X</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Mascarenhas</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Pollak</surname><given-names>M</given-names></name></person-group><article-title>Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)</article-title>. <source>J. Natl Cancer Inst.</source><volume>93</volume>(<issue>24</issue>), <fpage>1852</fpage>&#8211;<lpage>1857</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11752009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/93.24.1852</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritter</surname><given-names>CA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Perez-Torres</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Rinehart</surname><given-names>C</given-names></name></person-group><etal/><article-title>Human breast cancer cells selected for resistance to trastuzumab <italic toggle="yes">in vivo</italic> overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network</article-title>. <source>Clin. Cancer Res.</source><volume>13</volume>(<issue>16</issue>), <fpage>4909</fpage>&#8211;<lpage>4919</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17699871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-07-0701</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nahta</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Yuan</surname><given-names>LX</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kobayashi</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Esteva</surname><given-names>FJ</given-names></name></person-group><article-title>Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells</article-title>. <source>Cancer Res.</source><volume>65</volume>(<issue>23</issue>), <fpage>11118</fpage>&#8211;<lpage>11128</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16322262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-04-3841</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ordonez-Ercan</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Fan</surname><given-names>Z</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Edgerton</surname><given-names>SM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Thor</surname><given-names>AD</given-names></name></person-group><article-title>Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells</article-title>. <source>Int. J. Cancer</source><volume>120</volume>(<issue>9</issue>), <fpage>1874</fpage>&#8211;<lpage>1882</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17266042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.22423</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanabria-Figueroa</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Donnelly</surname><given-names>SM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name></person-group><etal/><article-title>Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1</article-title>. <source>Mol. Pharmacol.</source><volume>87</volume>(<issue>2</issue>), <fpage>150</fpage>&#8211;<lpage>161</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25391374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.114.095380</pub-id><pub-id pub-id-type="pmcid">PMC4293451</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>DN</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Sergina</surname><given-names>N</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ahuja</surname><given-names>D</given-names></name></person-group><etal/><article-title>Resiliency and vulnerability in the HER2-HER3 tumorigenic driver</article-title>. <source>Sci. Transl. Med.</source><volume>2</volume>(<issue>16</issue>), <fpage>16ra17</fpage> (<year>2010</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3000389</pub-id><pub-id pub-id-type="pmcid">PMC3033659</pub-id><pub-id pub-id-type="pmid">20371474</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serra</surname><given-names>V</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Scaltriti</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Prudkin</surname><given-names>L</given-names></name></person-group><etal/><article-title>PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer</article-title>. <source>Oncogene</source><volume>30</volume>(<issue>22</issue>), <fpage>2547</fpage>&#8211;<lpage>2557</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21278786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2010.626</pub-id><pub-id pub-id-type="pmcid">PMC3107390</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yen</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Benlimame</surname><given-names>N</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nie</surname><given-names>ZR</given-names></name></person-group><etal/><article-title>Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers</article-title>. <source>Mol. Biol. Cell</source><volume>13</volume>(<issue>11</issue>), <fpage>4029</fpage>&#8211;<lpage>4044</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12429844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.E02-02-0084</pub-id><pub-id pub-id-type="pmcid">PMC133612</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajkumar</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Stamp</surname><given-names>GW</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hughes</surname><given-names>CM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gullick</surname><given-names>WJ</given-names></name></person-group><article-title>c-erbB3 protein expression in ovarian cancer</article-title>. <source>Clin. Mol. Pathol.</source><volume>49</volume>(<issue>4</issue>), <fpage>M199</fpage>&#8211;<lpage>202</lpage> (<year>1996</year>).<pub-id pub-id-type="pmid">16696074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/mp.49.4.m199</pub-id><pub-id pub-id-type="pmcid">PMC408058</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>AK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Liang</surname><given-names>K</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>DiGiovanna</surname><given-names>MP</given-names></name></person-group><article-title>Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer</article-title>. <source>Cancer Res.</source><volume>68</volume>(<issue>5</issue>), <fpage>1538</fpage>&#8211;<lpage>1545</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18316619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-07-5935</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarden</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Sliwkowski</surname><given-names>MX</given-names></name></person-group><article-title>Untangling the ErbB signalling network</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>2</volume>(<issue>2</issue>), <fpage>127</fpage>&#8211;<lpage>137</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11252954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35052073</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baselga</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Swain</surname><given-names>SM</given-names></name></person-group><article-title>Novel anticancer targets: revisiting ERBB2 and discovering ERBB3</article-title>. <source>Nat. Rev. Cancer</source><volume>9</volume>(<issue>7</issue>), <fpage>463</fpage>&#8211;<lpage>475</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19536107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc2656</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollak</surname><given-names>MN</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Schernhammer</surname><given-names>ES</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hankinson</surname><given-names>SE</given-names></name></person-group><article-title>Insulin-like growth factors and neoplasia</article-title>. <source>Nat. Rev. Cancer</source><volume>4</volume>(<issue>7</issue>), <fpage>505</fpage>&#8211;<lpage>518</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15229476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1387</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollak</surname><given-names>MN</given-names></name></person-group><article-title>Insulin-like growth factors and neoplasia</article-title>. <source>Novartis Foundation Symposium</source><volume>262</volume>, <fpage>84</fpage>&#8211;<lpage>98</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15562824</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wygle</surname><given-names>RM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Overholser</surname><given-names>JP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Bekaii-Saab</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PTP</given-names></name></person-group><article-title>Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title>. <source>J. Immunol.</source><volume>191</volume>(<issue>1</issue>), <fpage>217</fpage>&#8211;<lpage>227</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23698748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1300231</pub-id><pub-id pub-id-type="pmcid">PMC4324564</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Overholser</surname><given-names>JP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nahta</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PTP</given-names></name></person-group><article-title>HER-3 peptide vaccines/mimics: combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells</article-title>. <source>Oncoimmunology</source><volume>3</volume>(<issue>11</issue>), <fpage>e956012</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25941588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/21624011.2014.956012</pub-id><pub-id pub-id-type="pmcid">PMC4368151</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vicari</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Liotta</surname><given-names>EM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways</article-title>. <source>J. Biol. Chem.</source><volume>286</volume>(<issue>15</issue>), <fpage>13612</fpage>&#8211;<lpage>13625</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21321115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M110.216812</pub-id><pub-id pub-id-type="pmcid">PMC3075706</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Moldovan</surname><given-names>N</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Carson</surname><given-names>WE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PTP</given-names></name></person-group><article-title>Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title>. <source>OncoImmunology</source><volume>1</volume>(<issue>7</issue>), <fpage>0</fpage>&#8211;<lpage>1</lpage> (<year>2012</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/onci.20708</pub-id><pub-id pub-id-type="pmcid">PMC3494619</pub-id><pub-id pub-id-type="pmid">23170253</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Overholser</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Donnelly</surname><given-names>SM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nahta</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PTP</given-names></name></person-group><article-title>IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides</article-title>. <source>Oncoimmunology</source><volume>3</volume>(<issue>11</issue>), <fpage>e956005</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25941587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/21624011.2014.956005</pub-id><pub-id pub-id-type="pmcid">PMC4368154</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zi</surname><given-names>X</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Pollak</surname><given-names>M</given-names></name></person-group><article-title>Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells</article-title>. <source>Int. J. Cancer</source><volume>108</volume>(<issue>3</issue>), <fpage>334</fpage>&#8211;<lpage>341</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">14648698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.11445</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haluska</surname><given-names>P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Carboni</surname><given-names>JM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>TenEyck</surname><given-names>C</given-names></name></person-group><etal/><article-title>HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924</article-title>. <source>Mol. Cancer Ther.</source><volume>7</volume>(<issue>9</issue>), <fpage>2589</fpage>&#8211;<lpage>2598</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18765823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-08-0493</pub-id><pub-id pub-id-type="pmcid">PMC2614316</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>AV</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gupta</surname><given-names>P</given-names></name></person-group><etal/><article-title>Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose</article-title>. <source>Cancer Chemother. Pharmacol.</source> (<year>2011</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-011-1806-6</pub-id><pub-id pub-id-type="pmid">22203367</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>G</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Haber</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Crocker</surname><given-names>LM</given-names></name></person-group><etal/><article-title>A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies</article-title>. <source>Cancer Cell</source><volume>20</volume>(<issue>4</issue>), <fpage>472</fpage>&#8211;<lpage>486</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">22014573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccr.2011.09.003</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radinsky</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Risin</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Fan</surname><given-names>D</given-names></name></person-group><etal/><article-title>Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells</article-title>. <source>Clin. Cancer Res.</source><volume>1</volume>(<issue>1</issue>), <fpage>19</fpage>&#8211;<lpage>31</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">9815883</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluftinger</surname><given-names>AM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Robinson</surname><given-names>BW</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Quenville</surname><given-names>NF</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Finley</surname><given-names>RJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Davis</surname><given-names>NL</given-names></name></person-group><article-title>Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer</article-title>. <source>Surg. Oncol.</source><volume>1</volume>(<issue>1</issue>), <fpage>97</fpage>&#8211;<lpage>105</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1285215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0960-7404(92)90062-p</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciardiello</surname><given-names>F</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tortora</surname><given-names>G</given-names></name></person-group><article-title>EGFR antagonists in cancer treatment</article-title>. <source>N. Engl. J. Med.</source><volume>358</volume>(<issue>11</issue>), <fpage>1160</fpage>&#8211;<lpage>1174</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18337605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra0707704</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciardiello</surname><given-names>F</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>De</surname><given-names>Vita F</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Orditura</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Comunale</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Galizia</surname><given-names>G</given-names></name></person-group><article-title>Cetuximab in the treatment of colorectal cancer</article-title>. <source>Future Oncol.</source><volume>1</volume>(<issue>2</issue>), <fpage>173</fpage>&#8211;<lpage>181</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16555987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14796694.1.2.173</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karapetis</surname><given-names>CS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Khambata-Ford</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Jonker</surname><given-names>DJ</given-names></name></person-group><etal/><article-title>K-ras mutations and benefit from cetuximab in advanced colorectal cancer</article-title>. <source>N. Engl. J. Med.</source><volume>359</volume>(<issue>17</issue>), <fpage>1757</fpage>&#8211;<lpage>1765</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18946061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0804385</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="other"><collab>Cancer Facts &amp; Figures 2020</collab>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf">www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf</ext-link></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friess</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kleeff</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Korc</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Buchler</surname><given-names>MW</given-names></name></person-group><article-title>Molecular aspects of pancreatic cancer and future perspectives</article-title>. <source>Dig. Surg.</source><volume>16</volume>(<issue>4</issue>), <fpage>281</fpage>&#8211;<lpage>290</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10449972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000018737</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowery</surname><given-names>MA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>EM</given-names></name></person-group><article-title>New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy</article-title>. <source>BioDrugs</source><volume>25</volume>(<issue>4</issue>), <fpage>207</fpage>&#8211;<lpage>216</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21815696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11592470-000000000-00000</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yakar</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Leroith</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Brodt</surname><given-names>P</given-names></name></person-group><article-title>The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models</article-title>. <source>Cytokine Growth Factor Rev.</source><volume>16</volume>(<issue>4&#8211;5</issue>), <fpage>407</fpage>&#8211;<lpage>420</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15886048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2005.01.010</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoeltzing</surname><given-names>O</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Reinmuth</surname><given-names>N</given-names></name></person-group><etal/><article-title>Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer</article-title>. <source>Am. J. Pathol.</source><volume>163</volume>(<issue>3</issue>), <fpage>1001</fpage>&#8211;<lpage>1011</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12937141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9440(10)63460-8</pub-id><pub-id pub-id-type="pmcid">PMC1868239</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishiwata</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Bergmann</surname><given-names>U</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kornmann</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lopez</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Beger</surname><given-names>HG</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Korc</surname><given-names>M</given-names></name></person-group><article-title>Altered expression of insulin-like growth factor II receptor in human pancreatic cancer</article-title>. <source>Pancreas</source><volume>15</volume>(<issue>4</issue>), <fpage>367</fpage>&#8211;<lpage>373</lpage> (<year>1997</year>).<pub-id pub-id-type="pmid">9361090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00006676-199711000-00006</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>TE</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Epa</surname><given-names>VC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Garrett</surname><given-names>TP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ward</surname><given-names>CW</given-names></name></person-group><article-title>Structure and function of the type 1 insulin-like growth factor receptor</article-title>. <source>Cell. Mol. Life Sci.</source><volume>57</volume>(<issue>7</issue>), <fpage>1050</fpage>&#8211;<lpage>1093</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10961344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/PL00000744</pub-id><pub-id pub-id-type="pmcid">PMC11146944</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergmann</surname><given-names>U</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Funatomi</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Yokoyama</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Beger</surname><given-names>HG</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Korc</surname><given-names>M</given-names></name></person-group><article-title>Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles</article-title>. <source>Cancer Res.</source><volume>55</volume>(<issue>10</issue>), <fpage>2007</fpage>&#8211;<lpage>2011</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7743492</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Siegel</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ward</surname><given-names>E</given-names></name></person-group><article-title>Cancer statistics, 2010</article-title>. <source>CA Cancer J. Clin.</source><volume>60</volume>(<issue>5</issue>), <fpage>277</fpage>&#8211;<lpage>300</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20610543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.20073</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cartwright</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Richards</surname><given-names>DA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Boehm</surname><given-names>KA</given-names></name></person-group><article-title>Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network</article-title>. <source>Cancer Control.</source><volume>15</volume>(<issue>4</issue>), <fpage>308</fpage>&#8211;<lpage>313</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18813198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/107327480801500405</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valsecchi</surname><given-names>ME</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>McDonald</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Brody</surname><given-names>JR</given-names></name></person-group><etal/><article-title>Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma</article-title>. <source>Cancer</source><volume>118</volume>(<issue>14</issue>), <fpage>3484</fpage>&#8211;<lpage>3493</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22086503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.26661</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Nio</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Guo</surname><given-names>KJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tamura</surname><given-names>K</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tian</surname><given-names>YL</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Dong</surname><given-names>YT</given-names></name></person-group><article-title>Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer</article-title>. <source>Anticancer Res.</source><volume>18</volume>(<issue>6B</issue>), <fpage>4613</fpage>&#8211;<lpage>4619</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9891528</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherwood</surname><given-names>ER</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Van Dongen</surname><given-names>JL</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wood</surname><given-names>CG</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Liao</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kozlowski</surname><given-names>JM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name></person-group><article-title>Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells</article-title>. <source>Br. J. Cancer</source><volume>77</volume>(<issue>6</issue>), <fpage>855</fpage>&#8211;<lpage>861</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9528825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1998.142</pub-id><pub-id pub-id-type="pmcid">PMC2150082</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgillo</surname><given-names>F</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Woo</surname><given-names>JK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kim</surname><given-names>ES</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hong</surname><given-names>WK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lee</surname><given-names>HY</given-names></name></person-group><article-title>Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib</article-title>. <source>Cancer Res.</source><volume>66</volume>(<issue>20</issue>), <fpage>10100</fpage>&#8211;<lpage>10111</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">17047074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-06-1684</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuribayashi</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kataoka</surname><given-names>K</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kurabayashi</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Miura</surname><given-names>M</given-names></name></person-group><article-title>Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells</article-title>. <source>Endocrinology</source><volume>145</volume>(<issue>11</issue>), <fpage>4976</fpage>&#8211;<lpage>4984</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15271882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2004-0713</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guix</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Faber</surname><given-names>AC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wang</surname><given-names>SE</given-names></name></person-group><etal/><article-title>Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins</article-title>. <source>J. Clin. Invest.</source><volume>118</volume>(<issue>7</issue>), <fpage>2609</fpage>&#8211;<lpage>2619</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18568074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI34588</pub-id><pub-id pub-id-type="pmcid">PMC2430495</pub-id></mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foy</surname><given-names>KC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wygle</surname><given-names>RM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Overholser</surname><given-names>JP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Bekaii-Saab</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title>. <source>J. Immunol.</source><volume>191</volume>(<issue>1</issue>), <fpage>217</fpage>&#8211;<lpage>227</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23698748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1300231</pub-id><pub-id pub-id-type="pmcid">PMC4324564</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wennhold</surname><given-names>K</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Shimabukuro-Vornhagen</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>von Bergwelt-Baildon</surname><given-names>M</given-names></name></person-group><article-title>B cell-based cancer immunotherapy</article-title>. <source>Transfus Med. Hemother.</source><volume>46</volume>(<issue>1</issue>), <fpage>36</fpage>&#8211;<lpage>46</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31244580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000496166</pub-id><pub-id pub-id-type="pmcid">PMC6558332</pub-id></mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekaii-Saab</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wesolowski</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ahn</surname><given-names>DH</given-names></name></person-group><etal/><article-title>Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and nor-MDP adjuvant in patients with advanced solid tumors</article-title>. <source>Clin. Cancer Res.</source><volume>25</volume>(<issue>12</issue>), <fpage>3495</fpage>&#8211;<lpage>3507</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30804020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-18-3997</pub-id><pub-id pub-id-type="pmcid">PMC7159438</pub-id></mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emens</surname><given-names>LA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Darcy</surname><given-names>PK</given-names></name></person-group><etal/><article-title>Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape</article-title>. <source>Eur. J. Cancer</source><volume>81</volume>, <fpage>116</fpage>&#8211;<lpage>129</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28623775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2017.01.035</pub-id></mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farkona</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Diamandis</surname><given-names>EP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Blasutig</surname><given-names>IM</given-names></name></person-group><article-title>Cancer immunotherapy: the beginning of the end of cancer?</article-title><source>BMC Med.</source><volume>14</volume>, <fpage>73</fpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27151159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-016-0623-5</pub-id><pub-id pub-id-type="pmcid">PMC4858828</pub-id></mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>JS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>D&#8217;Angelo</surname><given-names>SP</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Minor</surname><given-names>D</given-names></name></person-group><etal/><article-title>Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase III trial</article-title>. <source>Lancet Oncol.</source><volume>16</volume>(<issue>4</issue>), <fpage>375</fpage>&#8211;<lpage>384</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25795410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(15)70076-8</pub-id></mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larkin</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gonzalez</surname><given-names>R</given-names></name></person-group><etal/><article-title>Combined nivolumab and ipilimumab or monotherapy in untreated melanoma</article-title>. <source>N. Engl. J. Med.</source><volume>373</volume>(<issue>1</issue>), <fpage>23</fpage>&#8211;<lpage>34</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26027431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1504030</pub-id><pub-id pub-id-type="pmcid">PMC5698905</pub-id></mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brahmer</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Reckamp</surname><given-names>KL</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Baas</surname><given-names>P</given-names></name></person-group><etal/><article-title>Nivolumab versus docetaxel in advanced squamous-cell non&#8211;small-cell lung cancer</article-title>. <source>N. Engl. J. Med.</source><volume>373</volume>(<issue>2</issue>), <fpage>123</fpage>&#8211;<lpage>135</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26028407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1504627</pub-id><pub-id pub-id-type="pmcid">PMC4681400</pub-id></mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>McDermott</surname><given-names>DF</given-names></name></person-group><etal/><article-title>Nivolumab versus everolimus in advanced renal-cell carcinoma</article-title>. <source>N. Engl. J. Med.</source><volume>373</volume>(<issue>19</issue>), <fpage>1803</fpage>&#8211;<lpage>1813</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26406148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1510665</pub-id><pub-id pub-id-type="pmcid">PMC5719487</pub-id></mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>C</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ribas</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wolchok</surname><given-names>JD</given-names></name></person-group><etal/><article-title>Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase I trial</article-title>. <source>Lancet</source><volume>384</volume>(<issue>9948</issue>), <fpage>1109</fpage>&#8211;<lpage>1117</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25034862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(14)60958-2</pub-id></mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borghaei</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Paz-Ares</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Horn</surname><given-names>L</given-names></name></person-group><etal/><article-title>Nivolumab versus docetaxel in advanced nonsquamous non&#8211;small-cell lung cancer</article-title>. <source>N. Engl. J. Med.</source><volume>373</volume>(<issue>17</issue>), <fpage>1627</fpage>&#8211;<lpage>1639</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26412456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1507643</pub-id><pub-id pub-id-type="pmcid">PMC5705936</pub-id></mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kumar</surname><given-names>AB</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Finnes</surname><given-names>H</given-names></name></person-group><etal/><article-title>Combining immune checkpoint inhibitors with conventional cancer therapy</article-title>. <source>Front. Immunol.</source><volume>9</volume>, <fpage>1739</fpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30100909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01739</pub-id><pub-id pub-id-type="pmcid">PMC6072836</pub-id></mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential</article-title>. <source>Cell</source><volume>161</volume>(<issue>2</issue>), <fpage>205</fpage>&#8211;<lpage>214</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25860605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.03.030</pub-id><pub-id pub-id-type="pmcid">PMC5905674</pub-id></mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanneman</surname><given-names>M</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Dranoff</surname><given-names>G</given-names></name></person-group><article-title>Combining immunotherapy and targeted therapies in cancer treatment</article-title>. <source>Nat. Rev. Cancer</source><volume>12</volume>(<issue>4</issue>), <fpage>237</fpage>&#8211;<lpage>251</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22437869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3237</pub-id><pub-id pub-id-type="pmcid">PMC3967236</pub-id></mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van</surname><given-names>der Burg SH</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Arens</surname><given-names>R</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ossendorp</surname><given-names>F</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>van Hall</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Melief</surname><given-names>CJ</given-names></name></person-group><article-title>Vaccines for established cancer: overcoming the challenges posed by immune evasion</article-title>. <source>Nat. Rev. Cancer</source><volume>16</volume>(<issue>4</issue>), <fpage>219</fpage>&#8211;<lpage>233</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26965076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc.2016.16</pub-id></mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakuishi</surname><given-names>K</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Apetoh</surname><given-names>L</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Sullivan</surname><given-names>JM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Blazar</surname><given-names>BR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kuchroo</surname><given-names>VK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Anderson</surname><given-names>AC</given-names></name></person-group><article-title>Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity</article-title>. <source>J. Exp. Med.</source><volume>207</volume>(<issue>10</issue>), <fpage>2187</fpage>&#8211;<lpage>2194</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20819927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20100643</pub-id><pub-id pub-id-type="pmcid">PMC2947065</pub-id></mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>SR</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Turnis</surname><given-names>ME</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Goldberg</surname><given-names>MV</given-names></name></person-group><etal/><article-title>Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape</article-title>. <source>Cancer Res.</source><volume>72</volume>(<issue>4</issue>), <fpage>917</fpage>&#8211;<lpage>927</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22186141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-11-1620</pub-id><pub-id pub-id-type="pmcid">PMC3288154</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>